JP2009542683A - Ｄ−アミノ酸オキシダーゼの縮合ヘテロ環式阻害剤 - Google Patents

Info

Publication number

JP2009542683A

JP2009542683A JP2009518342A JP2009518342A JP2009542683A JP 2009542683 A JP2009542683 A JP 2009542683A JP 2009518342 A JP2009518342 A JP 2009518342A JP 2009518342 A JP2009518342 A JP 2009518342A JP 2009542683 A JP2009542683 A JP 2009542683A

Authority

JP

Japan

Prior art keywords

substituted

unsubstituted

member selected

alkyl

heterocycloalkyl

Prior art date

2006-06-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 102000004674 D-amino-acid oxidase Human genes 0.000 title abstract description 33
• 108010003989 D-amino-acid oxidase Proteins 0.000 title abstract description 33
• 239000003112 inhibitor Substances 0.000 title abstract description 12
• 125000000623 heterocyclic group Chemical group 0.000 title description 8
• 150000001875 compounds Chemical class 0.000 claims abstract description 328
• 238000000034 method Methods 0.000 claims abstract description 152
• 208000002193 Pain Diseases 0.000 claims abstract description 103
• 229910052717 sulfur Inorganic materials 0.000 claims abstract description 94
• 230000036407 pain Effects 0.000 claims abstract description 81
• 229910052760 oxygen Inorganic materials 0.000 claims abstract description 70
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 57
• 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 43
• 208000035475 disorder Diseases 0.000 claims abstract description 35
• 230000004770 neurodegeneration Effects 0.000 claims abstract description 22
• 206010010904 Convulsion Diseases 0.000 claims abstract description 20
• 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 19
• 208000012902 Nervous system disease Diseases 0.000 claims abstract description 17
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
• 230000036461 convulsion Effects 0.000 claims abstract description 13
• 208000025966 Neurological disease Diseases 0.000 claims abstract description 11
• 206010003591 Ataxia Diseases 0.000 claims abstract description 8
• 125000000217 alkyl group Chemical group 0.000 claims description 120
• 125000003118 aryl group Chemical group 0.000 claims description 108
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 102
• 125000001072 heteroaryl group Chemical group 0.000 claims description 92
• 229910052739 hydrogen Inorganic materials 0.000 claims description 84
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 78
• 229910052731 fluorine Inorganic materials 0.000 claims description 68
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 56
• 150000002500 ions Chemical class 0.000 claims description 52
• MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 43
• 229930195711 D-Serine Natural products 0.000 claims description 43
• 229910052801 chlorine Inorganic materials 0.000 claims description 42
• 229910052794 bromium Inorganic materials 0.000 claims description 38
• 150000003839 salts Chemical class 0.000 claims description 38
• 229910052727 yttrium Inorganic materials 0.000 claims description 37
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 31
• 208000004296 neuralgia Diseases 0.000 claims description 30
• 208000021722 neuropathic pain Diseases 0.000 claims description 30
• 229910052799 carbon Inorganic materials 0.000 claims description 28
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 28
• 125000002252 acyl group Chemical group 0.000 claims description 27
• 125000004429 atom Chemical group 0.000 claims description 23
• 239000000651 prodrug Substances 0.000 claims description 22
• 229940002612 prodrug Drugs 0.000 claims description 22
• 201000010099 disease Diseases 0.000 claims description 21
• 229910052736 halogen Inorganic materials 0.000 claims description 21
• 201000000980 schizophrenia Diseases 0.000 claims description 20
• 125000003342 alkenyl group Chemical group 0.000 claims description 19
• 150000002367 halogens Chemical class 0.000 claims description 18
• 208000024827 Alzheimer disease Diseases 0.000 claims description 17
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
• 125000005842 heteroatom Chemical group 0.000 claims description 11
• 125000005647 linker group Chemical group 0.000 claims description 11
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 10
• HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 10
• 125000004122 cyclic group Chemical group 0.000 claims description 10
• 239000003937 drug carrier Substances 0.000 claims description 10
• 208000030507 AIDS Diseases 0.000 claims description 9
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 9
• 230000002981 neuropathic effect Effects 0.000 claims description 9
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
• 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 8
• 150000001767 cationic compounds Chemical class 0.000 claims description 8
• 230000001684 chronic effect Effects 0.000 claims description 8
• 150000002892 organic cations Chemical class 0.000 claims description 8
• 206010044652 trigeminal neuralgia Diseases 0.000 claims description 7
• 208000004983 Phantom Limb Diseases 0.000 claims description 6
• 206010056238 Phantom pain Diseases 0.000 claims description 6
• 125000003545 alkoxy group Chemical group 0.000 claims description 6
• 208000020431 spinal cord injury Diseases 0.000 claims description 6
• 208000018737 Parkinson disease Diseases 0.000 claims description 5
• 206010058019 Cancer Pain Diseases 0.000 claims description 4
• DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 4
• DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 4
• 208000001640 Fibromyalgia Diseases 0.000 claims description 4
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
• 230000005062 synaptic transmission Effects 0.000 claims description 3
• 208000008035 Back Pain Diseases 0.000 claims description 2
• 208000019695 Migraine disease Diseases 0.000 claims description 2
• 150000004677 hydrates Chemical class 0.000 claims description 2
• 206010027599 migraine Diseases 0.000 claims description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
• 229910052789 astatine Inorganic materials 0.000 claims 1
• 229960003077 cycloserine Drugs 0.000 claims 1
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 369
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 286
• 230000015572 biosynthetic process Effects 0.000 description 185
• 238000003786 synthesis reaction Methods 0.000 description 183
• 239000000203 mixture Substances 0.000 description 104
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
• -1 (cyclohexyl) methyl Chemical group 0.000 description 90
• 239000007787 solid Substances 0.000 description 87
• 239000000243 solution Substances 0.000 description 85
• 238000006243 chemical reaction Methods 0.000 description 61
• 238000003818 flash chromatography Methods 0.000 description 61
• 238000000746 purification Methods 0.000 description 60
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 59
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 58
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 56
• 238000011282 treatment Methods 0.000 description 54
• 238000010898 silica gel chromatography Methods 0.000 description 52
• 239000000460 chlorine Substances 0.000 description 51
• 238000004128 high performance liquid chromatography Methods 0.000 description 50
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 46
• 238000012360 testing method Methods 0.000 description 44
• 239000000741 silica gel Substances 0.000 description 42
• 229910002027 silica gel Inorganic materials 0.000 description 42
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 42
• 238000005481 NMR spectroscopy Methods 0.000 description 37
• 230000000694 effects Effects 0.000 description 37
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 35
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 34
• 230000015654 memory Effects 0.000 description 32
• 239000000047 product Substances 0.000 description 31
• 239000011734 sodium Substances 0.000 description 31
• 125000001424 substituent group Chemical group 0.000 description 30
• 230000013016 learning Effects 0.000 description 27
• 239000003921 oil Substances 0.000 description 26
• 239000011541 reaction mixture Substances 0.000 description 26
• 239000012267 brine Substances 0.000 description 25
• 235000019198 oils Nutrition 0.000 description 25
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
• 239000012043 crude product Substances 0.000 description 24
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
• 238000003756 stirring Methods 0.000 description 23
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 22
• 208000024891 symptom Diseases 0.000 description 22
• 241001465754 Metazoa Species 0.000 description 21
• 230000006378 damage Effects 0.000 description 21
• 238000009472 formulation Methods 0.000 description 20
• 208000004454 Hyperalgesia Diseases 0.000 description 19
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 19
• 150000001299 aldehydes Chemical class 0.000 description 19
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 17
• 238000002953 preparative HPLC Methods 0.000 description 17
• 208000000044 Amnesia Diseases 0.000 description 16
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
• 239000002253 acid Substances 0.000 description 16
• 239000000543 intermediate Substances 0.000 description 16
• 239000012044 organic layer Substances 0.000 description 16
• 239000002904 solvent Substances 0.000 description 16
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 16
• 208000000094 Chronic Pain Diseases 0.000 description 15
• 150000002148 esters Chemical class 0.000 description 15
• 206010012289 Dementia Diseases 0.000 description 14
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 14
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 14
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 14
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 14
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 14
• 208000010877 cognitive disease Diseases 0.000 description 14
• 239000003814 drug Substances 0.000 description 14
• 238000000105 evaporative light scattering detection Methods 0.000 description 14
• 208000014674 injury Diseases 0.000 description 14
• RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 14
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 14
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
• 229910052777 Praseodymium Inorganic materials 0.000 description 13
• 208000027418 Wounds and injury Diseases 0.000 description 13
• 210000004556 brain Anatomy 0.000 description 13
• 125000004432 carbon atom Chemical group C* 0.000 description 13
• 239000000706 filtrate Substances 0.000 description 13
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
• 239000000725 suspension Substances 0.000 description 13
• 208000031091 Amnestic disease Diseases 0.000 description 12
• 208000035154 Hyperesthesia Diseases 0.000 description 12
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 12
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
• 230000001965 increasing effect Effects 0.000 description 12
• 239000000463 material Substances 0.000 description 12
• 206010027175 memory impairment Diseases 0.000 description 12
• WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 12
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 11
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 11
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
• 230000006986 amnesia Effects 0.000 description 11
• 235000019253 formic acid Nutrition 0.000 description 11
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 11
• 229920006395 saturated elastomer Polymers 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• MFGHPIAIHLKMBC-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]thiophene-2-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1CC1=CSC(C=O)=C1 MFGHPIAIHLKMBC-UHFFFAOYSA-N 0.000 description 10
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 10
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 10
• 239000002585 base Substances 0.000 description 10
• 206010015037 epilepsy Diseases 0.000 description 10
• 230000006870 function Effects 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• CNIVWXIXRNMAHJ-UHFFFAOYSA-N 3-methyl-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=C(C(O)=O)NC2=C1SC=C2C CNIVWXIXRNMAHJ-UHFFFAOYSA-N 0.000 description 9
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 9
• 239000004480 active ingredient Substances 0.000 description 9
• 230000006735 deficit Effects 0.000 description 9
• 229940079593 drug Drugs 0.000 description 9
• 239000000284 extract Substances 0.000 description 9
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
• 230000005764 inhibitory process Effects 0.000 description 9
• 239000012071 phase Substances 0.000 description 9
• 238000007127 saponification reaction Methods 0.000 description 9
• 230000035807 sensation Effects 0.000 description 9
• 235000019615 sensations Nutrition 0.000 description 9
• 208000011580 syndromic disease Diseases 0.000 description 9
• 230000001154 acute effect Effects 0.000 description 8
• 208000005298 acute pain Diseases 0.000 description 8
• 206010053552 allodynia Diseases 0.000 description 8
• 238000004587 chromatography analysis Methods 0.000 description 8
• 230000008434 fear extinction Effects 0.000 description 8
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• 230000002085 persistent effect Effects 0.000 description 8
• 150000003233 pyrroles Chemical class 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 238000007363 ring formation reaction Methods 0.000 description 8
• 239000012453 solvate Substances 0.000 description 8
• 229930192474 thiophene Natural products 0.000 description 8
• PMHDSACGRKBACK-UHFFFAOYSA-N 4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C=CC2=C1C=C(C(=O)O)N2 PMHDSACGRKBACK-UHFFFAOYSA-N 0.000 description 7
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
• 208000019901 Anxiety disease Diseases 0.000 description 7
• 208000028698 Cognitive impairment Diseases 0.000 description 7
• PAEYAKGINDQUCT-UHFFFAOYSA-N Ethyl 2-pyrrolecarboxylate Chemical compound CCOC(=O)C1=CC=CN1 PAEYAKGINDQUCT-UHFFFAOYSA-N 0.000 description 7
• YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 7
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
• HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 7
• 208000006011 Stroke Diseases 0.000 description 7
• 125000002947 alkylene group Chemical group 0.000 description 7
• 238000003556 assay Methods 0.000 description 7
• 210000003169 central nervous system Anatomy 0.000 description 7
• BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 7
• 238000009833 condensation Methods 0.000 description 7
• 230000005494 condensation Effects 0.000 description 7
• 230000004064 dysfunction Effects 0.000 description 7
• 239000011737 fluorine Substances 0.000 description 7
• 239000004615 ingredient Substances 0.000 description 7
• 230000014759 maintenance of location Effects 0.000 description 7
• 239000012299 nitrogen atmosphere Substances 0.000 description 7
• 208000033808 peripheral neuropathy Diseases 0.000 description 7
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
• 230000006977 prepulse inhibition Effects 0.000 description 7
• 238000010992 reflux Methods 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• 238000004809 thin layer chromatography Methods 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• PPXUUPXQWDQNGO-UHFFFAOYSA-N 2-azidoacetic acid Chemical compound OC(=O)CN=[N+]=[N-] PPXUUPXQWDQNGO-UHFFFAOYSA-N 0.000 description 6
• AFEBFEJAYWJLIR-UHFFFAOYSA-N 2-chloro-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C(Cl)=CC2=C1C=C(C(=O)O)N2 AFEBFEJAYWJLIR-UHFFFAOYSA-N 0.000 description 6
• OWJRYNILRVVVFK-UHFFFAOYSA-N 2-chloro-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C(Cl)=CC2=C1C=C(C(=O)O)N2 OWJRYNILRVVVFK-UHFFFAOYSA-N 0.000 description 6
• SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 6
• HNROXXPBCUVOKZ-UHFFFAOYSA-N 2-methyl-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound N1C(C(O)=O)=CC2=C1C=C(C)S2 HNROXXPBCUVOKZ-UHFFFAOYSA-N 0.000 description 6
• NPHIFZXNCDKIAW-IHWYPQMZSA-N 3-[(z)-prop-1-enyl]-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=C(C(O)=O)NC2=C1OC=C2\C=C/C NPHIFZXNCDKIAW-IHWYPQMZSA-N 0.000 description 6
• VIERWJYIMVJYBQ-UHFFFAOYSA-N 3-formyl-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C=C(C=O)C2=C1C=C(C(=O)O)N2 VIERWJYIMVJYBQ-UHFFFAOYSA-N 0.000 description 6
• PCVIGYOOZPUNSI-UHFFFAOYSA-N 5-[(4-chlorophenyl)methyl]thiophene-2-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1CC1=CC=C(C=O)S1 PCVIGYOOZPUNSI-UHFFFAOYSA-N 0.000 description 6
• 241000282412 Homo Species 0.000 description 6
• 208000026139 Memory disease Diseases 0.000 description 6
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
• 230000036506 anxiety Effects 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 230000019771 cognition Effects 0.000 description 6
• 230000001149 cognitive effect Effects 0.000 description 6
• 230000003750 conditioning effect Effects 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
• KRPJGLCVEYTVBW-UHFFFAOYSA-N ethyl 6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound C1=CSC2=C1C=C(C(=O)OCC)N2 KRPJGLCVEYTVBW-UHFFFAOYSA-N 0.000 description 6
• 210000003414 extremity Anatomy 0.000 description 6
• 125000001153 fluoro group Chemical group F* 0.000 description 6
• HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical class O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 6
• 229910001411 inorganic cation Inorganic materials 0.000 description 6
• 210000000653 nervous system Anatomy 0.000 description 6
• 230000003647 oxidation Effects 0.000 description 6
• 238000007254 oxidation reaction Methods 0.000 description 6
• ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 6
• 230000002093 peripheral effect Effects 0.000 description 6
• 230000002265 prevention Effects 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
• 239000007858 starting material Substances 0.000 description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• MKNMFJGDGQHMER-UHFFFAOYSA-N 1-methyl-4h-pyrrolo[3,2-b]pyrrole-5-carboxylic acid Chemical compound N1C(C(O)=O)=CC2=C1C=CN2C MKNMFJGDGQHMER-UHFFFAOYSA-N 0.000 description 5
• WZMNTSZIYSQDAN-UHFFFAOYSA-N 2-bromo-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C(Br)=CC2=C1C=C(C(=O)O)N2 WZMNTSZIYSQDAN-UHFFFAOYSA-N 0.000 description 5
• MDPWNOVTUQUEHP-UHFFFAOYSA-N 2-fluoro-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C(F)=CC2=C1C=C(C(=O)O)N2 MDPWNOVTUQUEHP-UHFFFAOYSA-N 0.000 description 5
• GRTOFBWMOOTRLU-UHFFFAOYSA-N 3-bromo-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C=C(Br)C2=C1C=C(C(=O)O)N2 GRTOFBWMOOTRLU-UHFFFAOYSA-N 0.000 description 5
• UZISGOJIMQYLOK-UHFFFAOYSA-N 3-ethenyl-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C=C(C=C)C2=C1C=C(C(=O)O)N2 UZISGOJIMQYLOK-UHFFFAOYSA-N 0.000 description 5
• JOZWNDJXSGKSIE-UHFFFAOYSA-N 4-(2-phenylethyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC(CCC=2C=CC=CC=2)=C1 JOZWNDJXSGKSIE-UHFFFAOYSA-N 0.000 description 5
• MMAIBGHDBYQYDI-UHFFFAOYSA-N 4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C=CC2=C1C=C(C(=O)O)N2 MMAIBGHDBYQYDI-UHFFFAOYSA-N 0.000 description 5
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 5
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 5
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• 206010020751 Hypersensitivity Diseases 0.000 description 5
• 206010065390 Inflammatory pain Diseases 0.000 description 5
• 235000019502 Orange oil Nutrition 0.000 description 5
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 5
• 238000006069 Suzuki reaction reaction Methods 0.000 description 5
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 208000026935 allergic disease Diseases 0.000 description 5
• 239000007864 aqueous solution Substances 0.000 description 5
• 230000027455 binding Effects 0.000 description 5
• 210000001638 cerebellum Anatomy 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 239000012230 colorless oil Substances 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 230000003111 delayed effect Effects 0.000 description 5
• 238000010511 deprotection reaction Methods 0.000 description 5
• 238000003745 diagnosis Methods 0.000 description 5
• 238000010828 elution Methods 0.000 description 5
• 229940088598 enzyme Drugs 0.000 description 5
• 125000004185 ester group Chemical group 0.000 description 5
• UMMMPHUCNBOYFZ-UHFFFAOYSA-N ethyl 4-chloro-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound S1C=CC2=C1NC(C(=O)OCC)=C2Cl UMMMPHUCNBOYFZ-UHFFFAOYSA-N 0.000 description 5
• 125000004494 ethyl ester group Chemical group 0.000 description 5
• 238000003682 fluorination reaction Methods 0.000 description 5
• 125000004474 heteroalkylene group Chemical group 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 229910052740 iodine Inorganic materials 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 5
• 230000006984 memory degeneration Effects 0.000 description 5
• 208000023060 memory loss Diseases 0.000 description 5
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
• VONGYFFEWFJHNP-UHFFFAOYSA-N methyl 1h-pyrrole-2-carboxylate Chemical compound COC(=O)C1=CC=CN1 VONGYFFEWFJHNP-UHFFFAOYSA-N 0.000 description 5
• 210000005036 nerve Anatomy 0.000 description 5
• 210000002569 neuron Anatomy 0.000 description 5
• 239000010502 orange oil Substances 0.000 description 5
• 239000012074 organic phase Substances 0.000 description 5
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 5
• KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
• 239000012363 selectfluor Substances 0.000 description 5
• 150000003577 thiophenes Chemical class 0.000 description 5
• XGCDBGRZEKYHNV-UHFFFAOYSA-N 1,1-bis(diphenylphosphino)methane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CP(C=1C=CC=CC=1)C1=CC=CC=C1 XGCDBGRZEKYHNV-UHFFFAOYSA-N 0.000 description 4
• RORQKWXGJVJJRX-UHFFFAOYSA-N 1-benzyl-4h-pyrrolo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=CC=2NC(C(=O)O)=CC=2N1CC1=CC=CC=C1 RORQKWXGJVJJRX-UHFFFAOYSA-N 0.000 description 4
• MREIFUWKYMNYTK-UHFFFAOYSA-N 1H-pyrrole Chemical class C=1C=CNC=1.C=1C=CNC=1 MREIFUWKYMNYTK-UHFFFAOYSA-N 0.000 description 4
• CKPLXHJFZJDLLJ-UHFFFAOYSA-N 2-(2-phenylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound C=1C=2NC(C(=O)O)=CC=2SC=1CCC1=CC=CC=C1 CKPLXHJFZJDLLJ-UHFFFAOYSA-N 0.000 description 4
• QYINWXAPIIBHHF-UHFFFAOYSA-N 2-(2-phenylethyl)-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound S1C=2NC(C(=O)O)=CC=2C=C1CCC1=CC=CC=C1 QYINWXAPIIBHHF-UHFFFAOYSA-N 0.000 description 4
• SCKHGUSFTMZCQF-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound C=1C=2NC(C(=O)O)=CC=2SC=1CC1=CC=C(Cl)C=C1 SCKHGUSFTMZCQF-UHFFFAOYSA-N 0.000 description 4
• FVCMFZXIIQKSRR-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound S1C=2NC(C(=O)O)=CC=2C=C1CC1=CC=C(Cl)C=C1 FVCMFZXIIQKSRR-UHFFFAOYSA-N 0.000 description 4
• OFYWMXKWLYRDTQ-UHFFFAOYSA-N 2-bromo-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C(Br)=CC2=C1C=C(C(=O)O)N2 OFYWMXKWLYRDTQ-UHFFFAOYSA-N 0.000 description 4
• XAFRVVYPVBHBMA-UHFFFAOYSA-N 2-bromo-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound C1=C(Br)SC2=C1C=C(C(=O)O)N2 XAFRVVYPVBHBMA-UHFFFAOYSA-N 0.000 description 4
• YJHHTOLIHBFPMF-UHFFFAOYSA-N 2-fluoro-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound C1=C(F)SC2=C1C=C(C(=O)O)N2 YJHHTOLIHBFPMF-UHFFFAOYSA-N 0.000 description 4
• OHKSQQOKYBCIQE-UHFFFAOYSA-N 3-(2-phenylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=2NC(C(=O)O)=CC=2SC=C1CCC1=CC=CC=C1 OHKSQQOKYBCIQE-UHFFFAOYSA-N 0.000 description 4
• VLXSPKGTKZBELQ-UHFFFAOYSA-N 3-(trifluoromethyl)-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C=C(C(F)(F)F)C2=C1C=C(C(=O)O)N2 VLXSPKGTKZBELQ-UHFFFAOYSA-N 0.000 description 4
• SWTPUPKFKYYOEM-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound C=1SC=2NC(C(=O)O)=CC=2C=1CC1=CC=C(Cl)C=C1 SWTPUPKFKYYOEM-UHFFFAOYSA-N 0.000 description 4
• VJXSERLPOOWZGU-VOTSOKGWSA-N 3-[(e)-2-phenylethenyl]-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=2NC(C(=O)O)=CC=2OC=C1\C=C\C1=CC=CC=C1 VJXSERLPOOWZGU-VOTSOKGWSA-N 0.000 description 4
• WOCVITYACZJEKA-UHFFFAOYSA-N 3-[2-(4-chlorophenyl)ethyl]-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound C=1SC=2NC(C(=O)O)=CC=2C=1CCC1=CC=C(Cl)C=C1 WOCVITYACZJEKA-UHFFFAOYSA-N 0.000 description 4
• MLINZILODAUEOR-UHFFFAOYSA-N 3-benzyl-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound C=1SC=2NC(C(=O)O)=CC=2C=1CC1=CC=CC=C1 MLINZILODAUEOR-UHFFFAOYSA-N 0.000 description 4
• WQGQGYADKDKACG-UHFFFAOYSA-N 3-bromo-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C=C(Br)C2=C1C=C(C(=O)O)N2 WQGQGYADKDKACG-UHFFFAOYSA-N 0.000 description 4
• BFQKWXMSMYDJQT-UHFFFAOYSA-N 3-bromo-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound BrC1=CSC2=C1C=C(C(=O)O)N2 BFQKWXMSMYDJQT-UHFFFAOYSA-N 0.000 description 4
• FDGNVONVURZBLL-UHFFFAOYSA-N 3-chloro-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C=C(Cl)C2=C1C=C(C(=O)O)N2 FDGNVONVURZBLL-UHFFFAOYSA-N 0.000 description 4
• KFHSHROQKJEWRI-UHFFFAOYSA-N 3-cyano-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C=C(C#N)C2=C1C=C(C(=O)O)N2 KFHSHROQKJEWRI-UHFFFAOYSA-N 0.000 description 4
• IQTCTGHOLXRCLZ-UHFFFAOYSA-N 3-cyclopropyl-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=2NC(C(=O)O)=CC=2OC=C1C1CC1 IQTCTGHOLXRCLZ-UHFFFAOYSA-N 0.000 description 4
• IDGWVERCOKPLPJ-UHFFFAOYSA-N 3-ethyl-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=C(C(O)=O)NC2=C1OC=C2CC IDGWVERCOKPLPJ-UHFFFAOYSA-N 0.000 description 4
• URRUSJVVVSKZSH-UHFFFAOYSA-N 3-fluoro-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C=C(F)C2=C1C=C(C(=O)O)N2 URRUSJVVVSKZSH-UHFFFAOYSA-N 0.000 description 4
• IMVSZFMGQMCNCV-UHFFFAOYSA-N 3-fluoro-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C=C(F)C2=C1C=C(C(=O)O)N2 IMVSZFMGQMCNCV-UHFFFAOYSA-N 0.000 description 4
• POTNAEUKCBDAGH-UHFFFAOYSA-N 3-fluoro-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound FC1=CSC2=C1C=C(C(=O)O)N2 POTNAEUKCBDAGH-UHFFFAOYSA-N 0.000 description 4
• OOWPYBCJKPNETK-UHFFFAOYSA-N 3-methyl-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=C(C(O)=O)NC2=C1OC=C2C OOWPYBCJKPNETK-UHFFFAOYSA-N 0.000 description 4
• ARWYYJPZHRRUSX-UHFFFAOYSA-N 3-phenyl-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound C=1SC=2NC(C(=O)O)=CC=2C=1C1=CC=CC=C1 ARWYYJPZHRRUSX-UHFFFAOYSA-N 0.000 description 4
• SAYKNBQCVYQQJF-UHFFFAOYSA-N 4-(2-phenylethynyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC(C#CC=2C=CC=CC=2)=C1 SAYKNBQCVYQQJF-UHFFFAOYSA-N 0.000 description 4
• HTEXKHXVQFVUDB-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)ethyl]thiophene-3-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1CCC1=CSC=C1C=O HTEXKHXVQFVUDB-UHFFFAOYSA-N 0.000 description 4
• ZYSQCKYCBRQBHZ-UHFFFAOYSA-N 4-fluorofuran-2-carbaldehyde Chemical compound FC1=COC(C=O)=C1 ZYSQCKYCBRQBHZ-UHFFFAOYSA-N 0.000 description 4
• CBMDSKURMHSKDR-UHFFFAOYSA-N 5-(2-phenylethyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC=C1CCC1=CC=CC=C1 CBMDSKURMHSKDR-UHFFFAOYSA-N 0.000 description 4
• AYWGPLNIWWJDBT-UHFFFAOYSA-N 6-bromo-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=CSC2=C1NC(C(=O)O)=C2Br AYWGPLNIWWJDBT-UHFFFAOYSA-N 0.000 description 4
• UQSQOFVPIABDDO-UHFFFAOYSA-N 6-fluoro-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=CSC2=C1NC(C(=O)O)=C2F UQSQOFVPIABDDO-UHFFFAOYSA-N 0.000 description 4
• XWKVOVYOCKXSKA-UHFFFAOYSA-N 6-methyl-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=CSC2=C1NC(C(O)=O)=C2C XWKVOVYOCKXSKA-UHFFFAOYSA-N 0.000 description 4
• 208000001387 Causalgia Diseases 0.000 description 4
• 208000018652 Closed Head injury Diseases 0.000 description 4
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
• 208000030814 Eating disease Diseases 0.000 description 4
• UEXCJVNBTNXOEH-UHFFFAOYSA-N Ethynylbenzene Chemical group C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 4
• 208000019454 Feeding and Eating disease Diseases 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• 206010021143 Hypoxia Diseases 0.000 description 4
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
• 206010034912 Phobia Diseases 0.000 description 4
• 208000028017 Psychotic disease Diseases 0.000 description 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
• 239000000556 agonist Substances 0.000 description 4
• VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 239000000164 antipsychotic agent Substances 0.000 description 4
• 239000008346 aqueous phase Substances 0.000 description 4
• 230000006399 behavior Effects 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
• 201000011510 cancer Diseases 0.000 description 4
• 239000003153 chemical reaction reagent Substances 0.000 description 4
• 230000006999 cognitive decline Effects 0.000 description 4
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 4
• 230000001143 conditioned effect Effects 0.000 description 4
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
• 235000014632 disordered eating Nutrition 0.000 description 4
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
• YUIDGONLMDUWNF-UHFFFAOYSA-N ethyl 3-chloro-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound S1C=C(Cl)C2=C1C=C(C(=O)OCC)N2 YUIDGONLMDUWNF-UHFFFAOYSA-N 0.000 description 4
• PBTSJBSYRNYTCI-UHFFFAOYSA-N ethyl 4-bromo-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound S1C=CC2=C1NC(C(=O)OCC)=C2Br PBTSJBSYRNYTCI-UHFFFAOYSA-N 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
• 230000009610 hypersensitivity Effects 0.000 description 4
• 230000007954 hypoxia Effects 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
• ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
• IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 150000004702 methyl esters Chemical class 0.000 description 4
• UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 4
• POTVAILTNPOQJH-UHFFFAOYSA-N n,n-dimethyl-1-(5-phenylmethoxy-1h-indol-3-yl)methanamine Chemical compound C1=C2C(CN(C)C)=CNC2=CC=C1OCC1=CC=CC=C1 POTVAILTNPOQJH-UHFFFAOYSA-N 0.000 description 4
• 201000001119 neuropathy Diseases 0.000 description 4
• 230000007823 neuropathy Effects 0.000 description 4
• 231100000189 neurotoxic Toxicity 0.000 description 4
• 230000002887 neurotoxic effect Effects 0.000 description 4
• 230000007935 neutral effect Effects 0.000 description 4
• 208000019899 phobic disease Diseases 0.000 description 4
• 208000028173 post-traumatic stress disease Diseases 0.000 description 4
• BKZMULQSKYPQRC-UHFFFAOYSA-M potassium;1-benzyl-4h-pyrrolo[3,2-b]pyrrole-5-carboxylate Chemical compound [K+].C1=CC=2NC(C(=O)[O-])=CC=2N1CC1=CC=CC=C1 BKZMULQSKYPQRC-UHFFFAOYSA-M 0.000 description 4
• SFTRZXKYZFWBAW-UHFFFAOYSA-M potassium;1-methyl-4h-pyrrolo[3,2-b]pyrrole-5-carboxylate Chemical compound [K+].N1C(C([O-])=O)=CC2=C1C=CN2C SFTRZXKYZFWBAW-UHFFFAOYSA-M 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 239000002244 precipitate Substances 0.000 description 4
• 230000011514 reflex Effects 0.000 description 4
• 239000012047 saturated solution Substances 0.000 description 4
• 230000000451 tissue damage Effects 0.000 description 4
• 231100000827 tissue damage Toxicity 0.000 description 4
• 230000000472 traumatic effect Effects 0.000 description 4
• 208000009935 visceral pain Diseases 0.000 description 4
• SZRNBGXUGVUETL-UHFFFAOYSA-N (4-bromo-4,4-difluorobut-2-ynoxy)-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC#CC(F)(F)Br SZRNBGXUGVUETL-UHFFFAOYSA-N 0.000 description 3
• LVLCWVAVXNPOFF-UHFFFAOYSA-N (4-formylthiophen-3-yl)boronic acid Chemical compound OB(O)C1=CSC=C1C=O LVLCWVAVXNPOFF-UHFFFAOYSA-N 0.000 description 3
• WFZGXAGXMGHOBY-UHFFFAOYSA-N 1-(2-phenylethyl)pyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C=NN1CCC1=CC=CC=C1 WFZGXAGXMGHOBY-UHFFFAOYSA-N 0.000 description 3
• WOXHPHOZJMLUFE-UHFFFAOYSA-N 1-benzylpyrazole-4-carbaldehyde Chemical compound C1=C(C=O)C=NN1CC1=CC=CC=C1 WOXHPHOZJMLUFE-UHFFFAOYSA-N 0.000 description 3
• JNHZZTKKFSPICX-UHFFFAOYSA-N 1-benzylpyrrole-2-carbaldehyde Chemical compound O=CC1=CC=CN1CC1=CC=CC=C1 JNHZZTKKFSPICX-UHFFFAOYSA-N 0.000 description 3
• MMQJZQKFTWIATR-UHFFFAOYSA-N 1h-pyrazole;1h-pyrrole Chemical class C=1C=CNC=1.C=1C=NNC=1 MMQJZQKFTWIATR-UHFFFAOYSA-N 0.000 description 3
• ZAMFMWOTDLEXLY-UHFFFAOYSA-N 1h-pyrrole;1,3-thiazole Chemical class C=1C=CNC=1.C1=CSC=N1 ZAMFMWOTDLEXLY-UHFFFAOYSA-N 0.000 description 3
• FJOHEVFGRJBAIJ-UHFFFAOYSA-N 2,3-dibromo-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C(Br)=C(Br)C2=C1C=C(C(=O)O)N2 FJOHEVFGRJBAIJ-UHFFFAOYSA-N 0.000 description 3
• GVSQRFNIXVGOQE-UHFFFAOYSA-N 2-(trifluoromethyl)-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C(C(F)(F)F)=CC2=C1C=C(C(=O)O)N2 GVSQRFNIXVGOQE-UHFFFAOYSA-N 0.000 description 3
• NXSJJTSIZPKKMM-UHFFFAOYSA-N 2-benzyl-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C=1C=2NC(C(=O)O)=CC=2OC=1CC1=CC=CC=C1 NXSJJTSIZPKKMM-UHFFFAOYSA-N 0.000 description 3
• UKKYTLNKHZLUJR-UHFFFAOYSA-N 2-fluoro-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C(F)=CC2=C1C=C(C(=O)O)N2 UKKYTLNKHZLUJR-UHFFFAOYSA-N 0.000 description 3
• ILLLWINWDFYWES-UHFFFAOYSA-N 2-methyl-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound N1C(C(O)=O)=CC2=C1C=C(C)O2 ILLLWINWDFYWES-UHFFFAOYSA-N 0.000 description 3
• CUCMYHOPTSUPIM-UHFFFAOYSA-N 3-(2-phenylethyl)-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=2NC(C(=O)O)=CC=2OC=C1CCC1=CC=CC=C1 CUCMYHOPTSUPIM-UHFFFAOYSA-N 0.000 description 3
• KUYFPJWLZXCSOC-UHFFFAOYSA-N 3-(hydroxymethyl)-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=C(C(O)=O)NC2=C1OC=C2CO KUYFPJWLZXCSOC-UHFFFAOYSA-N 0.000 description 3
• JFPMXKAHUZNTHW-UHFFFAOYSA-N 3-[(4-chlorophenyl)methyl]-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=2NC(C(=O)O)=CC=2SC=C1CC1=CC=C(Cl)C=C1 JFPMXKAHUZNTHW-UHFFFAOYSA-N 0.000 description 3
• ILODFLMZZKTIDM-UHFFFAOYSA-N 3-benzyl-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=2NC(C(=O)O)=CC=2OC=C1CC1=CC=CC=C1 ILODFLMZZKTIDM-UHFFFAOYSA-N 0.000 description 3
• HDPBBBQTCSOYSB-UHFFFAOYSA-N 3-chloro-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound O1C=C(Cl)C2=C1C=C(C(=O)O)N2 HDPBBBQTCSOYSB-UHFFFAOYSA-N 0.000 description 3
• ZJEUUASQEZMUNP-UHFFFAOYSA-N 3-propan-2-yl-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=C(C(O)=O)NC2=C1OC=C2C(C)C ZJEUUASQEZMUNP-UHFFFAOYSA-N 0.000 description 3
• SUAKVCDYDUALQH-UHFFFAOYSA-N 4-(2-phenylethyl)furan-2-carbaldehyde Chemical compound O1C(C=O)=CC(CCC=2C=CC=CC=2)=C1 SUAKVCDYDUALQH-UHFFFAOYSA-N 0.000 description 3
• HZXKGUWZFQJRBG-UHFFFAOYSA-N 4-(trifluoromethyl)furan-2-carbaldehyde Chemical compound FC(F)(F)C1=COC(C=O)=C1 HZXKGUWZFQJRBG-UHFFFAOYSA-N 0.000 description 3
• HHZQGWSGBIVHSL-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl]thiophene-3-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1CC1=CSC=C1C=O HHZQGWSGBIVHSL-UHFFFAOYSA-N 0.000 description 3
• DBPMTQBXPQFOHN-VOTSOKGWSA-N 4-[(e)-2-phenylethenyl]furan-2-carbaldehyde Chemical compound O1C(C=O)=CC(\C=C\C=2C=CC=CC=2)=C1 DBPMTQBXPQFOHN-VOTSOKGWSA-N 0.000 description 3
• KEXIUNXGSUAMNN-UHFFFAOYSA-N 4-benzylfuran-2-carbaldehyde Chemical compound O1C(C=O)=CC(CC=2C=CC=CC=2)=C1 KEXIUNXGSUAMNN-UHFFFAOYSA-N 0.000 description 3
• MOKRBDCJFCISEK-UHFFFAOYSA-N 4-benzylthiophene-3-carbaldehyde Chemical compound O=CC1=CSC=C1CC1=CC=CC=C1 MOKRBDCJFCISEK-UHFFFAOYSA-N 0.000 description 3
• OONJRWDQJMBPMF-UHFFFAOYSA-N 4-bromo-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound S1C=CC2=C1NC(C(=O)O)=C2Br OONJRWDQJMBPMF-UHFFFAOYSA-N 0.000 description 3
• MRGBBKQOSUHKPF-UHFFFAOYSA-N 4-bromofuran-2-carbaldehyde Chemical compound BrC1=COC(C=O)=C1 MRGBBKQOSUHKPF-UHFFFAOYSA-N 0.000 description 3
• GZNONFRIPBEMRS-UHFFFAOYSA-N 4-cyclopropylfuran-2-carbaldehyde Chemical compound O1C(C=O)=CC(C2CC2)=C1 GZNONFRIPBEMRS-UHFFFAOYSA-N 0.000 description 3
• PPVKGKYHKXSMLK-UHFFFAOYSA-N 4-ethenylfuran-2-carbaldehyde Chemical compound C=CC1=COC(C=O)=C1 PPVKGKYHKXSMLK-UHFFFAOYSA-N 0.000 description 3
• BLHZUMDWLLFLJC-UHFFFAOYSA-N 4-methylfuran-2-carbaldehyde Chemical compound CC1=COC(C=O)=C1 BLHZUMDWLLFLJC-UHFFFAOYSA-N 0.000 description 3
• OGLXWEVJNNKWJY-UHFFFAOYSA-N 4-o-tert-butyl 5-o-methyl 2-bromofuro[3,2-b]pyrrole-4,5-dicarboxylate Chemical compound O1C(Br)=CC2=C1C=C(C(=O)OC)N2C(=O)OC(C)(C)C OGLXWEVJNNKWJY-UHFFFAOYSA-N 0.000 description 3
• RNFIHRJWAKWIEM-UHFFFAOYSA-N 4-propan-2-ylfuran-2-carbaldehyde Chemical compound CC(C)C1=COC(C=O)=C1 RNFIHRJWAKWIEM-UHFFFAOYSA-N 0.000 description 3
• DFUTWTAXOYDQRR-UHFFFAOYSA-N 5-(2-phenylethyl)thiophene-3-carbaldehyde Chemical compound O=CC1=CSC(CCC=2C=CC=CC=2)=C1 DFUTWTAXOYDQRR-UHFFFAOYSA-N 0.000 description 3
• MMRIITDPKNWJQI-VOTSOKGWSA-N 5-[(e)-2-phenylethenyl]thiophene-3-carbaldehyde Chemical compound O=CC1=CSC(\C=C\C=2C=CC=CC=2)=C1 MMRIITDPKNWJQI-VOTSOKGWSA-N 0.000 description 3
• IRNAKAVXOUFQTN-UHFFFAOYSA-N 5-[tert-butyl(dimethyl)silyl]oxy-2,2-difluoropent-3-yn-1-ol Chemical compound CC(C)(C)[Si](C)(C)OCC#CC(F)(F)CO IRNAKAVXOUFQTN-UHFFFAOYSA-N 0.000 description 3
• BEMMSXOPWRZIOY-UHFFFAOYSA-N 5-benzylfuran-2-carbaldehyde Chemical compound O1C(C=O)=CC=C1CC1=CC=CC=C1 BEMMSXOPWRZIOY-UHFFFAOYSA-N 0.000 description 3
• KURANAVGCJMDFR-UHFFFAOYSA-N 5-fluorothiophene-2-carbaldehyde Chemical compound FC1=CC=C(C=O)S1 KURANAVGCJMDFR-UHFFFAOYSA-N 0.000 description 3
• OVIQOPYSEFRDMV-UHFFFAOYSA-N 6-bromo-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=COC2=C1NC(C(=O)O)=C2Br OVIQOPYSEFRDMV-UHFFFAOYSA-N 0.000 description 3
• KHBZGQNVVAXNLK-UHFFFAOYSA-N 6-fluoro-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=COC2=C1NC(C(=O)O)=C2F KHBZGQNVVAXNLK-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 206010003805 Autism Diseases 0.000 description 3
• 208000020706 Autistic disease Diseases 0.000 description 3
• 208000017667 Chronic Disease Diseases 0.000 description 3
• 206010012239 Delusion Diseases 0.000 description 3
• 208000004547 Hallucinations Diseases 0.000 description 3
• 206010019196 Head injury Diseases 0.000 description 3
• 208000023105 Huntington disease Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 108090000862 Ion Channels Proteins 0.000 description 3
• 102000004310 Ion Channels Human genes 0.000 description 3
• 238000012347 Morris Water Maze Methods 0.000 description 3
• 241000699666 Mus <mouse, genus> Species 0.000 description 3
• 208000000112 Myalgia Diseases 0.000 description 3
• 206010028980 Neoplasm Diseases 0.000 description 3
• 208000028389 Nerve injury Diseases 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• 108010006152 Serine racemase Proteins 0.000 description 3
• 102100035717 Serine racemase Human genes 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 150000001241 acetals Chemical class 0.000 description 3
• 229960000583 acetic acid Drugs 0.000 description 3
• 150000001408 amides Chemical class 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 235000019270 ammonium chloride Nutrition 0.000 description 3
• 229940005529 antipsychotics Drugs 0.000 description 3
• 229910052796 boron Inorganic materials 0.000 description 3
• 150000001642 boronic acid derivatives Chemical class 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 150000001721 carbon Chemical group 0.000 description 3
• 150000001733 carboxylic acid esters Chemical class 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 208000015114 central nervous system disease Diseases 0.000 description 3
• 206010008118 cerebral infarction Diseases 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 239000000544 cholinesterase inhibitor Substances 0.000 description 3
• 230000003920 cognitive function Effects 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 231100000868 delusion Toxicity 0.000 description 3
• IPKKHRVROFYTEK-UHFFFAOYSA-N dipentyl phthalate Chemical compound CCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCC IPKKHRVROFYTEK-UHFFFAOYSA-N 0.000 description 3
• VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• YGSOAUAHZCWHPK-UHFFFAOYSA-N ethyl 2,3-dibromo-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound S1C(Br)=C(Br)C2=C1C=C(C(=O)OCC)N2 YGSOAUAHZCWHPK-UHFFFAOYSA-N 0.000 description 3
• RBTYQWWFSZMUBD-UHFFFAOYSA-N ethyl 2-(2-phenylethyl)-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound S1C=2NC(C(=O)OCC)=CC=2C=C1CCC1=CC=CC=C1 RBTYQWWFSZMUBD-UHFFFAOYSA-N 0.000 description 3
• DBUKGGCXHSFKQP-UHFFFAOYSA-N ethyl 2-(trifluoromethyl)-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C(C(F)(F)F)=CC2=C1C=C(C(=O)OCC)N2 DBUKGGCXHSFKQP-UHFFFAOYSA-N 0.000 description 3
• FOZNVCOTXKVHFH-UHFFFAOYSA-N ethyl 2-[(4-chlorophenyl)methyl]-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound C=1C=2NC(C(=O)OCC)=CC=2SC=1CC1=CC=C(Cl)C=C1 FOZNVCOTXKVHFH-UHFFFAOYSA-N 0.000 description 3
• NGPHTFGJRRQKMI-UHFFFAOYSA-N ethyl 2-[(4-chlorophenyl)methyl]-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound S1C=2NC(C(=O)OCC)=CC=2C=C1CC1=CC=C(Cl)C=C1 NGPHTFGJRRQKMI-UHFFFAOYSA-N 0.000 description 3
• LVFGFBHCDFCWEN-UHFFFAOYSA-N ethyl 2-azidoprop-2-enoate Chemical compound CCOC(=O)C(=C)N=[N+]=[N-] LVFGFBHCDFCWEN-UHFFFAOYSA-N 0.000 description 3
• BSIIENSVDCHCBF-UHFFFAOYSA-N ethyl 2-chloro-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C(Cl)=CC2=C1C=C(C(=O)OCC)N2 BSIIENSVDCHCBF-UHFFFAOYSA-N 0.000 description 3
• ZIGXACGLYBHAFH-UHFFFAOYSA-N ethyl 2-fluoro-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound S1C(F)=CC2=C1C=C(C(=O)OCC)N2 ZIGXACGLYBHAFH-UHFFFAOYSA-N 0.000 description 3
• PDHKWZKPXDTJKJ-UHFFFAOYSA-N ethyl 3-(trifluoromethyl)-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(C(F)(F)F)C2=C1C=C(C(=O)OCC)N2 PDHKWZKPXDTJKJ-UHFFFAOYSA-N 0.000 description 3
• VCEXEVDIFDQLIB-UHFFFAOYSA-N ethyl 3-[(4-chlorophenyl)methyl]-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound C1=2NC(C(=O)OCC)=CC=2SC=C1CC1=CC=C(Cl)C=C1 VCEXEVDIFDQLIB-UHFFFAOYSA-N 0.000 description 3
• AVBZZXGZHWTTQG-UHFFFAOYSA-N ethyl 3-[(4-chlorophenyl)methyl]-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound C=1SC=2NC(C(=O)OCC)=CC=2C=1CC1=CC=C(Cl)C=C1 AVBZZXGZHWTTQG-UHFFFAOYSA-N 0.000 description 3
• OOWDCGMCFQICNN-CMDGGOBGSA-N ethyl 3-[(e)-2-phenylethenyl]-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound C1=2NC(C(=O)OCC)=CC=2OC=C1\C=C\C1=CC=CC=C1 OOWDCGMCFQICNN-CMDGGOBGSA-N 0.000 description 3
• IMJNTKCUAGEOAO-UHFFFAOYSA-N ethyl 3-[2-(4-chlorophenyl)ethyl]-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound C=1SC=2NC(C(=O)OCC)=CC=2C=1CCC1=CC=C(Cl)C=C1 IMJNTKCUAGEOAO-UHFFFAOYSA-N 0.000 description 3
• KSONMHNRMJQMFE-UHFFFAOYSA-N ethyl 3-bromo-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound S1C=C(Br)C2=C1C=C(C(=O)OCC)N2 KSONMHNRMJQMFE-UHFFFAOYSA-N 0.000 description 3
• CKZIDWJZAWLTDL-UHFFFAOYSA-N ethyl 3-cyclopropyl-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound C1=2NC(C(=O)OCC)=CC=2OC=C1C1CC1 CKZIDWJZAWLTDL-UHFFFAOYSA-N 0.000 description 3
• FAXBFZSAJISWGE-UHFFFAOYSA-N ethyl 3-ethenyl-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(C=C)C2=C1C=C(C(=O)OCC)N2 FAXBFZSAJISWGE-UHFFFAOYSA-N 0.000 description 3
• MXGZRIGYSQKECK-UHFFFAOYSA-N ethyl 3-ethyl-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(CC)C2=C1C=C(C(=O)OCC)N2 MXGZRIGYSQKECK-UHFFFAOYSA-N 0.000 description 3
• WXBHZKGCCLZUGI-UHFFFAOYSA-N ethyl 3-fluoro-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound S1C=C(F)C2=C1C=C(C(=O)OCC)N2 WXBHZKGCCLZUGI-UHFFFAOYSA-N 0.000 description 3
• IVTSDPODKGCTGY-UHFFFAOYSA-N ethyl 3-methyl-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound S1C=C(C)C2=C1C=C(C(=O)OCC)N2 IVTSDPODKGCTGY-UHFFFAOYSA-N 0.000 description 3
• HQUBIVPIDNGDEQ-UHFFFAOYSA-N ethyl 3-propan-2-yl-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(C(C)C)C2=C1C=C(C(=O)OCC)N2 HQUBIVPIDNGDEQ-UHFFFAOYSA-N 0.000 description 3
• NNABKJKQNGGLKM-UHFFFAOYSA-N ethyl 4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=CC2=C1C=C(C(=O)OCC)N2 NNABKJKQNGGLKM-UHFFFAOYSA-N 0.000 description 3
• 238000001704 evaporation Methods 0.000 description 3
• 210000001508 eye Anatomy 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 238000007429 general method Methods 0.000 description 3
• 239000008187 granular material Substances 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• 208000028867 ischemia Diseases 0.000 description 3
• 230000008449 language Effects 0.000 description 3
• 201000003723 learning disability Diseases 0.000 description 3
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 230000008897 memory decline Effects 0.000 description 3
• NJMHLPYIHMAHRE-UHFFFAOYSA-N methyl 2-methyl-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C(C)=CC2=C1C=C(C(=O)OC)N2 NJMHLPYIHMAHRE-UHFFFAOYSA-N 0.000 description 3
• FBCFZDRUYPHONP-UHFFFAOYSA-N methyl 3-fluoro-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound FC1=CSC2=C1C=C(C(=O)OC)N2 FBCFZDRUYPHONP-UHFFFAOYSA-N 0.000 description 3
• LIIJOCBTGRORSY-UHFFFAOYSA-N methyl 4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=CC2=C1C=C(C(=O)OC)N2 LIIJOCBTGRORSY-UHFFFAOYSA-N 0.000 description 3
• CINAWYPBOKCJHH-UHFFFAOYSA-N methyl 6-fluoro-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound C1=CSC2=C1NC(C(=O)OC)=C2F CINAWYPBOKCJHH-UHFFFAOYSA-N 0.000 description 3
• BYUKOSRRSBTICX-UHFFFAOYSA-N methyl 6-methyl-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound C1=CSC2=C1NC(C(=O)OC)=C2C BYUKOSRRSBTICX-UHFFFAOYSA-N 0.000 description 3
• 208000031225 myocardial ischemia Diseases 0.000 description 3
• 230000008764 nerve damage Effects 0.000 description 3
• 230000008904 neural response Effects 0.000 description 3
• CTQNGGLPUBDAKN-UHFFFAOYSA-N o-dimethylbenzene Natural products CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 238000012746 preparative thin layer chromatography Methods 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 208000020016 psychiatric disease Diseases 0.000 description 3
• 239000003368 psychostimulant agent Substances 0.000 description 3
• DOYOPBSXEIZLRE-UHFFFAOYSA-N pyrrole-3-carboxylic acid Natural products OC(=O)C=1C=CNC=1 DOYOPBSXEIZLRE-UHFFFAOYSA-N 0.000 description 3
• 238000004007 reversed phase HPLC Methods 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 229910052710 silicon Inorganic materials 0.000 description 3
• 239000000377 silicon dioxide Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 229910052938 sodium sulfate Inorganic materials 0.000 description 3
• 235000011152 sodium sulphate Nutrition 0.000 description 3
• 150000003457 sulfones Chemical class 0.000 description 3
• 125000004434 sulfur atom Chemical group 0.000 description 3
• 238000013268 sustained release Methods 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 201000008914 temporal lobe epilepsy Diseases 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• HJPOQNKXQHXEKE-UHFFFAOYSA-N (1-benzylpyrazol-4-yl)methanol Chemical compound C1=C(CO)C=NN1CC1=CC=CC=C1 HJPOQNKXQHXEKE-UHFFFAOYSA-N 0.000 description 2
• JPYHYGZOZZUNGA-UHFFFAOYSA-N (1-benzylpyrrol-2-yl)methanol Chemical compound OCC1=CC=CN1CC1=CC=CC=C1 JPYHYGZOZZUNGA-UHFFFAOYSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• UVTUHTQNNGCVPI-UHFFFAOYSA-N (4-fluorofuran-2-yl)methanol Chemical compound OCC1=CC(F)=CO1 UVTUHTQNNGCVPI-UHFFFAOYSA-N 0.000 description 2
• UJQNOBISTKAIPR-UHFFFAOYSA-N (4-fluorothiophen-2-yl)methanol Chemical compound OCC1=CC(F)=CS1 UJQNOBISTKAIPR-UHFFFAOYSA-N 0.000 description 2
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
• JEXOBLNGJXHXPS-UHFFFAOYSA-N 1-(2-phenylethyl)pyrazole Chemical compound C=1C=CC=CC=1CCN1C=CC=N1 JEXOBLNGJXHXPS-UHFFFAOYSA-N 0.000 description 2
• OUKQTRFCDKSEPL-UHFFFAOYSA-N 1-Methyl-2-pyrrolecarboxaldehyde Chemical compound CN1C=CC=C1C=O OUKQTRFCDKSEPL-UHFFFAOYSA-N 0.000 description 2
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
• BVQPVBZRJSFOEZ-UHFFFAOYSA-N 1-chloro-4-(diethoxyphosphorylmethyl)benzene Chemical compound CCOP(=O)(OCC)CC1=CC=C(Cl)C=C1 BVQPVBZRJSFOEZ-UHFFFAOYSA-N 0.000 description 2
• 238000005160 1H NMR spectroscopy Methods 0.000 description 2
• RABBMOYULJIAFU-UHFFFAOYSA-N 1h-pyrrole;thiophene Chemical class C=1C=CNC=1.C=1C=CSC=1 RABBMOYULJIAFU-UHFFFAOYSA-N 0.000 description 2
• GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 2
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
• GNKMLUZRQKOBEF-UHFFFAOYSA-N 2-(2-phenylethyl)pyrazole-3-carbaldehyde Chemical compound O=CC1=CC=NN1CCC1=CC=CC=C1 GNKMLUZRQKOBEF-UHFFFAOYSA-N 0.000 description 2
• FZFGCHRSCIKKOX-UHFFFAOYSA-N 2-(bromomethyl)-4-(trifluoromethyl)furan Chemical compound FC(F)(F)C1=COC(CBr)=C1 FZFGCHRSCIKKOX-UHFFFAOYSA-N 0.000 description 2
• DXHCHIJMMKQRKR-UHFFFAOYSA-N 2-fluorothiophene Chemical compound FC1=CC=CS1 DXHCHIJMMKQRKR-UHFFFAOYSA-N 0.000 description 2
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 2
• RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 2
• TUFORXFWYVAOOP-UHFFFAOYSA-N 4-(2-phenylethynyl)furan-2-carbaldehyde Chemical compound O1C(C=O)=CC(C#CC=2C=CC=CC=2)=C1 TUFORXFWYVAOOP-UHFFFAOYSA-N 0.000 description 2
• UYHLIOFILQCDGR-UHFFFAOYSA-N 4-(2-trimethylsilylethoxymethyl)thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C=CC2=C1C=C(C(O)=O)N2COCC[Si](C)(C)C UYHLIOFILQCDGR-UHFFFAOYSA-N 0.000 description 2
• ZXSVWILBEKFPJA-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)ethenyl]thiophene-3-carbaldehyde Chemical compound C1=CC(Cl)=CC=C1C=CC1=CSC=C1C=O ZXSVWILBEKFPJA-UHFFFAOYSA-N 0.000 description 2
• PDONIKHDXYHTLS-UHFFFAOYSA-N 4-bromothiophene-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=C1 PDONIKHDXYHTLS-UHFFFAOYSA-N 0.000 description 2
• ZDVHJQOCVBTMOF-UHFFFAOYSA-N 4-bromothiophene-3-carbaldehyde Chemical compound BrC1=CSC=C1C=O ZDVHJQOCVBTMOF-UHFFFAOYSA-N 0.000 description 2
• 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 2
• AAWOXRNFSSSREJ-UHFFFAOYSA-N 4-fluorothiophene-2-carbaldehyde Chemical compound FC1=CSC(C=O)=C1 AAWOXRNFSSSREJ-UHFFFAOYSA-N 0.000 description 2
• IBWSJGDUGPZUJV-UHFFFAOYSA-N 4-phenylthiophene-3-carbaldehyde Chemical compound O=CC1=CSC=C1C1=CC=CC=C1 IBWSJGDUGPZUJV-UHFFFAOYSA-N 0.000 description 2
• VOROEQBFPPIACJ-UHFFFAOYSA-N 5-Phosphononorvaline Chemical compound OC(=O)C(N)CCCP(O)(O)=O VOROEQBFPPIACJ-UHFFFAOYSA-N 0.000 description 2
• CDBAAGJKGCQYLA-UHFFFAOYSA-N 5-fluorothiophene-3-carbaldehyde Chemical compound FC1=CC(C=O)=CS1 CDBAAGJKGCQYLA-UHFFFAOYSA-N 0.000 description 2
• QJHLCUOJRLTPSI-UHFFFAOYSA-N 5-formyl-3-methylfuran-2-carboxylic acid Chemical compound CC=1C=C(C=O)OC=1C(O)=O QJHLCUOJRLTPSI-UHFFFAOYSA-N 0.000 description 2
• FYSLNKSSHFIUCC-UHFFFAOYSA-N 6-chloro-4h-furo[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=COC2=C1NC(C(=O)O)=C2Cl FYSLNKSSHFIUCC-UHFFFAOYSA-N 0.000 description 2
• IARHDLPYCCGSKT-UHFFFAOYSA-N 6-chloro-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound C1=CSC2=C1NC(C(=O)O)=C2Cl IARHDLPYCCGSKT-UHFFFAOYSA-N 0.000 description 2
• NUYPMIRKFLHBNC-UHFFFAOYSA-N 6-o-tert-butyl 5-o-ethyl 2-bromothieno[2,3-b]pyrrole-5,6-dicarboxylate Chemical compound C1=C(Br)SC2=C1C=C(C(=O)OCC)N2C(=O)OC(C)(C)C NUYPMIRKFLHBNC-UHFFFAOYSA-N 0.000 description 2
• WMMSKVADYMCPTL-UHFFFAOYSA-N 6-o-tert-butyl 5-o-ethyl thieno[2,3-b]pyrrole-5,6-dicarboxylate Chemical compound C1=CSC2=C1C=C(C(=O)OCC)N2C(=O)OC(C)(C)C WMMSKVADYMCPTL-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 208000006888 Agnosia Diseases 0.000 description 2
• 241001047040 Agnosia Species 0.000 description 2
• 241001535291 Analges Species 0.000 description 2
• 206010003062 Apraxia Diseases 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 2
• 239000005711 Benzoic acid Substances 0.000 description 2
• 208000020925 Bipolar disease Diseases 0.000 description 2
• 208000014644 Brain disease Diseases 0.000 description 2
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• 206010008025 Cerebellar ataxia Diseases 0.000 description 2
• 102000000018 Chemokine CCL2 Human genes 0.000 description 2
• 201000006082 Chickenpox Diseases 0.000 description 2
• 150000008569 D-serines Chemical class 0.000 description 2
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
• 201000010374 Down Syndrome Diseases 0.000 description 2
• 208000032274 Encephalopathy Diseases 0.000 description 2
• 208000027776 Extrapyramidal disease Diseases 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 208000010496 Heart Arrest Diseases 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 208000020358 Learning disease Diseases 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 208000019022 Mood disease Diseases 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 206010028570 Myelopathy Diseases 0.000 description 2
• KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• 206010028923 Neonatal asphyxia Diseases 0.000 description 2
• 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 2
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 2
• 208000008589 Obesity Diseases 0.000 description 2
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
• 206010037779 Radiculopathy Diseases 0.000 description 2
• 206010072005 Spinal pain Diseases 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 206010046980 Varicella Diseases 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• VKIJXFIYBAYHOE-VOTSOKGWSA-N [(e)-2-phenylethenyl]boronic acid Chemical compound OB(O)\C=C\C1=CC=CC=C1 VKIJXFIYBAYHOE-VOTSOKGWSA-N 0.000 description 2
• DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 230000003281 allosteric effect Effects 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 230000000202 analgesic effect Effects 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 229940005524 anti-dementia drug Drugs 0.000 description 2
• 239000000935 antidepressant agent Substances 0.000 description 2
• 229940005513 antidepressants Drugs 0.000 description 2
• 229940054051 antipsychotic indole derivative Drugs 0.000 description 2
• 201000007201 aphasia Diseases 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 238000002820 assay format Methods 0.000 description 2
• 230000035045 associative learning Effects 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 235000010233 benzoic acid Nutrition 0.000 description 2
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
• OBXSGRKNCOCTTM-UHFFFAOYSA-N benzyl diethyl phosphate Chemical compound CCOP(=O)(OCC)OCC1=CC=CC=C1 OBXSGRKNCOCTTM-UHFFFAOYSA-N 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
• 238000009835 boiling Methods 0.000 description 2
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
• 230000005978 brain dysfunction Effects 0.000 description 2
• 230000031709 bromination Effects 0.000 description 2
• 238000005893 bromination reaction Methods 0.000 description 2
• 150000001735 carboxylic acids Chemical class 0.000 description 2
• 238000005660 chlorination reaction Methods 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
• 230000037410 cognitive enhancement Effects 0.000 description 2
• 239000002475 cognitive enhancer Substances 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
• 230000006866 deterioration Effects 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 229940043279 diisopropylamine Drugs 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 238000004821 distillation Methods 0.000 description 2
• 229960003530 donepezil Drugs 0.000 description 2
• 229960003638 dopamine Drugs 0.000 description 2
• 206010013663 drug dependence Diseases 0.000 description 2
• 239000003596 drug target Substances 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 230000002996 emotional effect Effects 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 150000002170 ethers Chemical class 0.000 description 2
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
• DJQCWYZOWVCBEM-UHFFFAOYSA-N ethyl 1-benzyl-4h-pyrrolo[3,2-b]pyrrole-5-carboxylate Chemical compound C1=CC=2NC(C(=O)OCC)=CC=2N1CC1=CC=CC=C1 DJQCWYZOWVCBEM-UHFFFAOYSA-N 0.000 description 2
• RXJWDJMFTFKADU-UHFFFAOYSA-N ethyl 1-benzyl-6H-pyrrolo[2,3-c]pyrazole-5-carboxylate Chemical compound C1=2NC(C(=O)OCC)=CC=2C=NN1CC1=CC=CC=C1 RXJWDJMFTFKADU-UHFFFAOYSA-N 0.000 description 2
• CUTDJCLKKQWXGM-UHFFFAOYSA-N ethyl 1-benzylpyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC1=CC=CC=C1 CUTDJCLKKQWXGM-UHFFFAOYSA-N 0.000 description 2
• BJZSJXBOHBVOKH-UHFFFAOYSA-N ethyl 1-methyl-4h-pyrrolo[3,2-b]pyrrole-5-carboxylate Chemical compound CN1C=CC2=C1C=C(C(=O)OCC)N2 BJZSJXBOHBVOKH-UHFFFAOYSA-N 0.000 description 2
• BRRNEOTUICFFJO-UHFFFAOYSA-N ethyl 2-(2-phenylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound C=1C=2NC(C(=O)OCC)=CC=2SC=1CCC1=CC=CC=C1 BRRNEOTUICFFJO-UHFFFAOYSA-N 0.000 description 2
• QLFZCCPLTLIWTK-UHFFFAOYSA-N ethyl 2-(4-chlorobenzoyl)-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound S1C=2NC(C(=O)OCC)=CC=2C=C1C(=O)C1=CC=C(Cl)C=C1 QLFZCCPLTLIWTK-UHFFFAOYSA-N 0.000 description 2
• SEXGWGJXHDQQDY-UHFFFAOYSA-N ethyl 2-azido-3-(4-benzylfuran-2-yl)prop-2-enoate Chemical compound O1C(C=C(C(=O)OCC)N=[N+]=[N-])=CC(CC=2C=CC=CC=2)=C1 SEXGWGJXHDQQDY-UHFFFAOYSA-N 0.000 description 2
• BVEQPQVAYIFRCK-UHFFFAOYSA-N ethyl 2-azido-3-(4-fluorothiophen-2-yl)prop-2-enoate Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC(F)=CS1 BVEQPQVAYIFRCK-UHFFFAOYSA-N 0.000 description 2
• VDRZDKAEMRQURL-UHFFFAOYSA-N ethyl 2-azido-3-(5-benzylfuran-2-yl)prop-2-enoate Chemical compound O1C(C=C(C(=O)OCC)N=[N+]=[N-])=CC=C1CC1=CC=CC=C1 VDRZDKAEMRQURL-UHFFFAOYSA-N 0.000 description 2
• GMHVTKGBAZYUHW-UHFFFAOYSA-N ethyl 2-azido-3-(5-fluorofuran-2-yl)prop-2-enoate Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC=C(F)O1 GMHVTKGBAZYUHW-UHFFFAOYSA-N 0.000 description 2
• XHELTWFUFRUTPH-UHFFFAOYSA-N ethyl 2-azido-3-(5-fluorothiophen-2-yl)prop-2-enoate Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC=C(F)S1 XHELTWFUFRUTPH-UHFFFAOYSA-N 0.000 description 2
• DBYWTQSBIHSINZ-UHFFFAOYSA-N ethyl 2-azido-3-(5-methylthiophen-2-yl)prop-2-enoate Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC=C(C)S1 DBYWTQSBIHSINZ-UHFFFAOYSA-N 0.000 description 2
• WNEKBYWOAQMLLY-UHFFFAOYSA-N ethyl 2-benzyl-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound C=1C=2NC(C(=O)OCC)=CC=2OC=1CC1=CC=CC=C1 WNEKBYWOAQMLLY-UHFFFAOYSA-N 0.000 description 2
• KXGSKTSSCQBDOA-UHFFFAOYSA-N ethyl 2-bromo-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound S1C(Br)=CC2=C1C=C(C(=O)OCC)N2 KXGSKTSSCQBDOA-UHFFFAOYSA-N 0.000 description 2
• IXGBRRWUBAVAFD-UHFFFAOYSA-N ethyl 2-fluoro-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C(F)=CC2=C1C=C(C(=O)OCC)N2 IXGBRRWUBAVAFD-UHFFFAOYSA-N 0.000 description 2
• XZWXDDXLKJETRG-UHFFFAOYSA-N ethyl 2-fluoro-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound C1=C(F)SC2=C1C=C(C(=O)OCC)N2 XZWXDDXLKJETRG-UHFFFAOYSA-N 0.000 description 2
• OWWISVHKUJKEQH-UHFFFAOYSA-N ethyl 2-methyl-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound S1C(C)=CC2=C1C=C(C(=O)OCC)N2 OWWISVHKUJKEQH-UHFFFAOYSA-N 0.000 description 2
• OCAZMBQKNNYUBP-UHFFFAOYSA-N ethyl 3-(2-phenylethyl)-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound C1=2NC(C(=O)OCC)=CC=2OC=C1CCC1=CC=CC=C1 OCAZMBQKNNYUBP-UHFFFAOYSA-N 0.000 description 2
• GUPVCCGLMZBFIR-UHFFFAOYSA-N ethyl 3-(2-phenylethyl)-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound C1=2NC(C(=O)OCC)=CC=2SC=C1CCC1=CC=CC=C1 GUPVCCGLMZBFIR-UHFFFAOYSA-N 0.000 description 2
• YMXHMJXEIUCOLH-UHFFFAOYSA-N ethyl 3-(2-tert-butylsilyloxypropan-2-yl)-4H-furo[3,2-b]pyrrole-5-carboxylate Chemical compound C(C)(C)(C)[SiH2]OC(C1=COC2=C1NC(=C2)C(=O)OCC)(C)C YMXHMJXEIUCOLH-UHFFFAOYSA-N 0.000 description 2
• UREYLMFRWAPIHQ-UHFFFAOYSA-N ethyl 3-benzyl-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound C1=2NC(C(=O)OCC)=CC=2OC=C1CC1=CC=CC=C1 UREYLMFRWAPIHQ-UHFFFAOYSA-N 0.000 description 2
• OEMMLLJQDKJIPQ-UHFFFAOYSA-N ethyl 3-benzyl-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound C=1SC=2NC(C(=O)OCC)=CC=2C=1CC1=CC=CC=C1 OEMMLLJQDKJIPQ-UHFFFAOYSA-N 0.000 description 2
• BRCYQLJSKNOAFL-UHFFFAOYSA-N ethyl 3-bromo-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(Br)C2=C1C=C(C(=O)OCC)N2 BRCYQLJSKNOAFL-UHFFFAOYSA-N 0.000 description 2
• LQGXFBUNQQNLKA-UHFFFAOYSA-N ethyl 3-bromo-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound BrC1=CSC2=C1C=C(C(=O)OCC)N2 LQGXFBUNQQNLKA-UHFFFAOYSA-N 0.000 description 2
• GMQBSQREBGIUFK-UHFFFAOYSA-N ethyl 3-chloro-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(Cl)C2=C1C=C(C(=O)OCC)N2 GMQBSQREBGIUFK-UHFFFAOYSA-N 0.000 description 2
• WYFWXZCADUWGGH-UHFFFAOYSA-N ethyl 3-methyl-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(C)C2=C1C=C(C(=O)OCC)N2 WYFWXZCADUWGGH-UHFFFAOYSA-N 0.000 description 2
• OQWHBCIKOUGKFT-UHFFFAOYSA-N ethyl 3-phenyl-6h-thieno[2,3-b]pyrrole-5-carboxylate Chemical compound C=1SC=2NC(C(=O)OCC)=CC=2C=1C1=CC=CC=C1 OQWHBCIKOUGKFT-UHFFFAOYSA-N 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 208000033699 familial Guillain-Barre syndrome Diseases 0.000 description 2
• 230000006390 fear memory Effects 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical class O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 2
• 239000012362 glacial acetic acid Substances 0.000 description 2
• 229940093915 gynecological organic acid Drugs 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• 230000026030 halogenation Effects 0.000 description 2
• 238000005658 halogenation reaction Methods 0.000 description 2
• 238000010438 heat treatment Methods 0.000 description 2
• 239000004312 hexamethylene tetramine Substances 0.000 description 2
• 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
• RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 2
• 208000013403 hyperactivity Diseases 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 239000012535 impurity Substances 0.000 description 2
• 150000002475 indoles Chemical class 0.000 description 2
• 239000012442 inert solvent Substances 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
• 239000012280 lithium aluminium hydride Substances 0.000 description 2
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
• WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 2
• NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 230000001404 mediated effect Effects 0.000 description 2
• 230000009245 menopause Effects 0.000 description 2
• ASHPSTQAODFMLF-UHFFFAOYSA-N methyl 1-benzylpyrrole-2-carboxylate Chemical compound COC(=O)C1=CC=CN1CC1=CC=CC=C1 ASHPSTQAODFMLF-UHFFFAOYSA-N 0.000 description 2
• VDJYJSUDISVNRS-UHFFFAOYSA-N methyl 2-(trifluoromethoxy)benzoate Chemical compound COC(=O)C1=CC=CC=C1OC(F)(F)F VDJYJSUDISVNRS-UHFFFAOYSA-N 0.000 description 2
• MNKSOBXLSSJMIF-UHFFFAOYSA-N methyl 6-bromo-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound C1=COC2=C1NC(C(=O)OC)=C2Br MNKSOBXLSSJMIF-UHFFFAOYSA-N 0.000 description 2
• QVQYZWXETCGKKZ-UHFFFAOYSA-N methyl 6-fluoro-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound C1=COC2=C1NC(C(=O)OC)=C2F QVQYZWXETCGKKZ-UHFFFAOYSA-N 0.000 description 2
• GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
• 238000000465 moulding Methods 0.000 description 2
• 201000006417 multiple sclerosis Diseases 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 230000007658 neurological function Effects 0.000 description 2
• 230000003040 nociceptive effect Effects 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 235000020824 obesity Nutrition 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 235000005985 organic acids Nutrition 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• 208000019906 panic disease Diseases 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 208000035824 paresthesia Diseases 0.000 description 2
• 208000033300 perinatal asphyxia Diseases 0.000 description 2
• 239000003208 petroleum Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
• 239000000902 placebo Substances 0.000 description 2
• 229940068196 placebo Drugs 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 238000001671 psychotherapy Methods 0.000 description 2
• LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• KIWUVOGUEXMXSV-UHFFFAOYSA-N rhodanine Chemical compound O=C1CSC(=S)N1 KIWUVOGUEXMXSV-UHFFFAOYSA-N 0.000 description 2
• 230000000698 schizophrenic effect Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 230000009155 sensory pathway Effects 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• 239000012279 sodium borohydride Substances 0.000 description 2
• 229910000033 sodium borohydride Inorganic materials 0.000 description 2
• 235000009518 sodium iodide Nutrition 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 210000001032 spinal nerve Anatomy 0.000 description 2
• TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 229940124530 sulfonamide Drugs 0.000 description 2
• 150000003456 sulfonamides Chemical class 0.000 description 2
• HZTCVVJJSBKXMA-UHFFFAOYSA-N tert-butyl-[(3,3-difluoro-2h-furan-5-yl)methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(F)(F)CO1 HZTCVVJJSBKXMA-UHFFFAOYSA-N 0.000 description 2
• ZUNINWFVODGKGI-UHFFFAOYSA-N tert-butyl-[(4-fluorofuran-2-yl)methoxy]-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCC1=CC(F)=CO1 ZUNINWFVODGKGI-UHFFFAOYSA-N 0.000 description 2
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 125000005309 thioalkoxy group Chemical group 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 238000006478 transmetalation reaction Methods 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 210000003901 trigeminal nerve Anatomy 0.000 description 2
• PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
• ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 229920002554 vinyl polymer Polymers 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 230000003936 working memory Effects 0.000 description 2
• QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
• QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
• PXZNJHHUYJRFPZ-UHFFFAOYSA-N (4-bromothiophen-2-yl)methanol Chemical compound OCC1=CC(Br)=CS1 PXZNJHHUYJRFPZ-UHFFFAOYSA-N 0.000 description 1
• ABNTYKOJPTVOSK-UHFFFAOYSA-N (4-bromothiophen-2-yl)methoxy-tert-butyl-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OCC1=CC(Br)=CS1 ABNTYKOJPTVOSK-UHFFFAOYSA-N 0.000 description 1
• ANQLQOQLYYSYQP-UHFFFAOYSA-N (5-fluorothiophen-2-yl)methanol Chemical compound OCC1=CC=C(F)S1 ANQLQOQLYYSYQP-UHFFFAOYSA-N 0.000 description 1
• JUWYQISLQJRRNT-UHFFFAOYSA-N (5-formylfuran-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)O1 JUWYQISLQJRRNT-UHFFFAOYSA-N 0.000 description 1
• WKKQLNQKSANODS-UHFFFAOYSA-N (5-formylfuran-3-yl)methyl benzoate Chemical compound O1C(C=O)=CC(COC(=O)C=2C=CC=CC=2)=C1 WKKQLNQKSANODS-UHFFFAOYSA-N 0.000 description 1
• DEQOVKFWRPOPQP-UHFFFAOYSA-N (5-formylthiophen-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)S1 DEQOVKFWRPOPQP-UHFFFAOYSA-N 0.000 description 1
• ZCUFJAORCNFWOF-UHFFFAOYSA-N (5-formylthiophen-3-yl)boronic acid Chemical compound OB(O)C1=CSC(C=O)=C1 ZCUFJAORCNFWOF-UHFFFAOYSA-N 0.000 description 1
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
• PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
• MDAOZTFXAXKOTE-UHFFFAOYSA-N 1,5-dihydropyrrolo[3,4-b]pyrrole Chemical class N1C=C2NC=CC2=C1 MDAOZTFXAXKOTE-UHFFFAOYSA-N 0.000 description 1
• VWDXBYMJWCBQHM-UHFFFAOYSA-N 1,5-dihydropyrrolo[3,4-b]pyrrole-2-carboxylic acid Chemical class N1C=C2NC(C(=O)O)=CC2=C1 VWDXBYMJWCBQHM-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
• DOHJTIXLBCEKQC-UHFFFAOYSA-N 1h-furo[3,4-b]pyrrole-2-carboxylic acid Chemical class O1C=C2NC(C(=O)O)=CC2=C1 DOHJTIXLBCEKQC-UHFFFAOYSA-N 0.000 description 1
• LRGBDJBDJXZTTD-UHFFFAOYSA-N 1h-pyrazole-4-carbaldehyde Chemical compound O=CC=1C=NNC=1 LRGBDJBDJXZTTD-UHFFFAOYSA-N 0.000 description 1
• ICFGFAUMBISMLR-UHFFFAOYSA-N 1h-pyrazole-5-carbaldehyde Chemical compound O=CC=1C=CNN=1 ICFGFAUMBISMLR-UHFFFAOYSA-N 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• JFGOCNAOOLXIMV-UHFFFAOYSA-N 2,3-dichloro-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C(Cl)=C(Cl)C2=C1C=C(C(=O)O)N2 JFGOCNAOOLXIMV-UHFFFAOYSA-N 0.000 description 1
• UQABPUYRHQRGLU-UHFFFAOYSA-N 2,3-dichloro-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound ClC1=C(Cl)SC2=C1C=C(C(=O)O)N2 UQABPUYRHQRGLU-UHFFFAOYSA-N 0.000 description 1
• RQWCPZNVQXZQIG-UHFFFAOYSA-N 2,4-dichloro-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound S1C(Cl)=CC2=C1NC(C(=O)O)=C2Cl RQWCPZNVQXZQIG-UHFFFAOYSA-N 0.000 description 1
• SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
• HWSDRAPTZRYXHN-UHFFFAOYSA-N 2-(4-chlorophenyl)ethenylboronic acid Chemical compound OB(O)C=CC1=CC=C(Cl)C=C1 HWSDRAPTZRYXHN-UHFFFAOYSA-N 0.000 description 1
• BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
• 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• LILXDMFJXYAKMK-UHFFFAOYSA-N 2-bromo-1,1-diethoxyethane Chemical compound CCOC(CBr)OCC LILXDMFJXYAKMK-UHFFFAOYSA-N 0.000 description 1
• IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
• OVXJWSYBABKZMD-UHFFFAOYSA-N 2-chloro-1,1-diethoxyethane Chemical compound CCOC(CCl)OCC OVXJWSYBABKZMD-UHFFFAOYSA-N 0.000 description 1
• SOGNHUJSAKAIRG-UHFFFAOYSA-N 2-chloro-6h-thieno[2,3-b]pyrrole-5-carboxylic acid Chemical compound C1=C(Cl)SC2=C1C=C(C(=O)O)N2 SOGNHUJSAKAIRG-UHFFFAOYSA-N 0.000 description 1
• PAUZWINNRRQSPP-UHFFFAOYSA-N 2-cyano-4h-thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C(C#N)=CC2=C1C=C(C(=O)O)N2 PAUZWINNRRQSPP-UHFFFAOYSA-N 0.000 description 1
• FZOKMMKREHLHBP-UHFFFAOYSA-N 2-fluoro-4-(2-trimethylsilylethoxymethyl)thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C(F)=CC2=C1C=C(C(O)=O)N2COCC[Si](C)(C)C FZOKMMKREHLHBP-UHFFFAOYSA-N 0.000 description 1
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• JYUOZYKKKGDMKH-UHFFFAOYSA-N 2-methyl-4-(trifluoromethyl)furan Chemical compound CC1=CC(C(F)(F)F)=CO1 JYUOZYKKKGDMKH-UHFFFAOYSA-N 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
• OXDSTEQMQRCOGK-UHFFFAOYSA-N 3-fluorothiophene-2-carbaldehyde Chemical compound FC=1C=CSC=1C=O OXDSTEQMQRCOGK-UHFFFAOYSA-N 0.000 description 1
• 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• BNYIQEFWGSXIKQ-UHFFFAOYSA-N 3-methylfuran-2-carboxylic acid Chemical compound CC=1C=COC=1C(O)=O BNYIQEFWGSXIKQ-UHFFFAOYSA-N 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
• XBXZTENDDALBBV-UHFFFAOYSA-N 4,4-difluoropent-2-yne-1,5-diol Chemical compound OCC#CC(F)(F)CO XBXZTENDDALBBV-UHFFFAOYSA-N 0.000 description 1
• CHRAVDVWAPGZOY-UHFFFAOYSA-N 4,5-dibromothiophene-2-carbaldehyde Chemical compound BrC=1C=C(C=O)SC=1Br CHRAVDVWAPGZOY-UHFFFAOYSA-N 0.000 description 1
• YHEMDDZDHYKQGZ-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)furan-2-carbaldehyde Chemical compound O1C(C)(C)C(C)(C)OB1C1=COC(C=O)=C1 YHEMDDZDHYKQGZ-UHFFFAOYSA-N 0.000 description 1
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
• AXCTUMLEPJKRIX-IHWYPQMZSA-N 4-[(z)-prop-1-enyl]furan-2-carbaldehyde Chemical compound C\C=C/C1=COC(C=O)=C1 AXCTUMLEPJKRIX-IHWYPQMZSA-N 0.000 description 1
• RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
• MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
• QSXQHBKWSNXBEZ-UHFFFAOYSA-N 4-fluorothiophene-3-carbaldehyde Chemical compound FC1=CSC=C1C=O QSXQHBKWSNXBEZ-UHFFFAOYSA-N 0.000 description 1
• HVXCGIPRXBJIRK-UHFFFAOYSA-N 4-methylthiophene-2-carbaldehyde Chemical compound CC1=CSC(C=O)=C1 HVXCGIPRXBJIRK-UHFFFAOYSA-N 0.000 description 1
• STJZAPSUEPQINW-UHFFFAOYSA-N 4-o-tert-butyl 5-o-methyl furo[3,2-b]pyrrole-4,5-dicarboxylate Chemical compound O1C=CC2=C1C=C(C(=O)OC)N2C(=O)OC(C)(C)C STJZAPSUEPQINW-UHFFFAOYSA-N 0.000 description 1
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
• YFMUACLZRVJOBK-UHFFFAOYSA-N 5-(2-phenylethynyl)thiophene-2-carbaldehyde Chemical compound S1C(C=O)=CC=C1C#CC1=CC=CC=C1 YFMUACLZRVJOBK-UHFFFAOYSA-N 0.000 description 1
• KLVCIHFXPHKSPD-UHFFFAOYSA-N 5-(trifluoromethyl)furan-2-carbaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)O1 KLVCIHFXPHKSPD-UHFFFAOYSA-N 0.000 description 1
• VAUMDUIUEPIGHM-UHFFFAOYSA-N 5-Methyl-2-thiophenecarboxaldehyde Chemical compound CC1=CC=C(C=O)S1 VAUMDUIUEPIGHM-UHFFFAOYSA-N 0.000 description 1
• GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
• VWYFITBWBRVBSW-UHFFFAOYSA-N 5-chlorothiophene-2-carbaldehyde Chemical compound ClC1=CC=C(C=O)S1 VWYFITBWBRVBSW-UHFFFAOYSA-N 0.000 description 1
• SHNRXUWGUKDPMA-UHFFFAOYSA-N 5-formyl-2-furoic acid Chemical compound OC(=O)C1=CC=C(C=O)O1 SHNRXUWGUKDPMA-UHFFFAOYSA-N 0.000 description 1
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
• SEWHHLSEXYDKMQ-UHFFFAOYSA-N 5-iodothiophene-3-carbaldehyde Chemical compound IC1=CC(C=O)=CS1 SEWHHLSEXYDKMQ-UHFFFAOYSA-N 0.000 description 1
• CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
• GELCPPPIKQQUEJ-UHFFFAOYSA-N 6-fluoro-4-(2-trimethylsilylethoxymethyl)thieno[3,2-b]pyrrole-5-carboxylic acid Chemical compound S1C=CC2=C1C(F)=C(C(O)=O)N2COCC[Si](C)(C)C GELCPPPIKQQUEJ-UHFFFAOYSA-N 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
• 206010000087 Abdominal pain upper Diseases 0.000 description 1
• 206010001497 Agitation Diseases 0.000 description 1
• 101710134784 Agnoprotein Proteins 0.000 description 1
• 208000007848 Alcoholism Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 208000000103 Anorexia Nervosa Diseases 0.000 description 1
• 206010002652 Anorgasmia Diseases 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 208000036487 Arthropathies Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 208000032841 Bulimia Diseases 0.000 description 1
• 206010006550 Bulimia nervosa Diseases 0.000 description 1
• PUOZPEBSERMLTQ-UHFFFAOYSA-N C1=COC2=C1NC(C(=O)O)=C2I Chemical compound C1=COC2=C1NC(C(=O)O)=C2I PUOZPEBSERMLTQ-UHFFFAOYSA-N 0.000 description 1
• VGJSQNCLVSEWCU-UHFFFAOYSA-N CN(C)CC1=C(NC2=C1SC=C2)C(=O)O Chemical compound CN(C)CC1=C(NC2=C1SC=C2)C(=O)O VGJSQNCLVSEWCU-UHFFFAOYSA-N 0.000 description 1
• 206010006895 Cachexia Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 206010064012 Central pain syndrome Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 206010008479 Chest Pain Diseases 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 description 1
• 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 206010010144 Completed suicide Diseases 0.000 description 1
• 206010057254 Connective tissue inflammation Diseases 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 229920000742 Cotton Polymers 0.000 description 1
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 206010013886 Dysaesthesia Diseases 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• 206010014498 Embolic stroke Diseases 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
• 102000005915 GABA Receptors Human genes 0.000 description 1
• 108010005551 GABA Receptors Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 102000018899 Glutamate Receptors Human genes 0.000 description 1
• 108010027915 Glutamate Receptors Proteins 0.000 description 1
• 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
• 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 241001559542 Hippocampus hippocampus Species 0.000 description 1
• 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010051161 Hyperglucagonaemia Diseases 0.000 description 1
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
• 208000031226 Hyperlipidaemia Diseases 0.000 description 1
• 206010065952 Hyperpathia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 208000004044 Hypesthesia Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 208000005168 Intussusception Diseases 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
• 102100035792 Kininogen-1 Human genes 0.000 description 1
• 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
• 229930195714 L-glutamate Natural products 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• 229910052765 Lutetium Inorganic materials 0.000 description 1
• 206010026749 Mania Diseases 0.000 description 1
• 208000021964 McLeod neuroacanthocytosis syndrome Diseases 0.000 description 1
• 208000026486 McLeod syndrome Diseases 0.000 description 1
• DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 101100189356 Mus musculus Papolb gene Proteins 0.000 description 1
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
• 206010028836 Neck pain Diseases 0.000 description 1
• 206010029174 Nerve compression Diseases 0.000 description 1
• 208000031264 Nerve root compression Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 208000001294 Nociceptive Pain Diseases 0.000 description 1
• 229910003849 O-Si Inorganic materials 0.000 description 1
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
• 102000004316 Oxidoreductases Human genes 0.000 description 1
• 108090000854 Oxidoreductases Proteins 0.000 description 1
• 229910003872 O—Si Inorganic materials 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 101150003085 Pdcl gene Proteins 0.000 description 1
• PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
• GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 206010036618 Premenstrual syndrome Diseases 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 102000002067 Protein Subunits Human genes 0.000 description 1
• 108010001267 Protein Subunits Proteins 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
• 206010039966 Senile dementia Diseases 0.000 description 1
• 201000001880 Sexual dysfunction Diseases 0.000 description 1
• 229910004298 SiO 2 Inorganic materials 0.000 description 1
• XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 206010041250 Social phobia Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 206010044688 Trisomy 21 Diseases 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• 206010064390 Tumour invasion Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• CBMCZKMIOZYAHS-IHWYPQMZSA-N [(z)-prop-1-enyl]boronic acid Chemical compound C\C=C/B(O)O CBMCZKMIOZYAHS-IHWYPQMZSA-N 0.000 description 1
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 208000027093 acute inflammatory demyelinating polyradiculoneuropathy Diseases 0.000 description 1
• 208000026345 acute stress disease Diseases 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 238000012382 advanced drug delivery Methods 0.000 description 1
• 230000007000 age related cognitive decline Effects 0.000 description 1
• 201000007930 alcohol dependence Diseases 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 150000001335 aliphatic alkanes Chemical class 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 125000003282 alkyl amino group Chemical group 0.000 description 1
• 125000004414 alkyl thio group Chemical group 0.000 description 1
• 125000005237 alkyleneamino group Chemical group 0.000 description 1
• 125000005238 alkylenediamino group Chemical group 0.000 description 1
• 125000005530 alkylenedioxy group Chemical group 0.000 description 1
• 125000005529 alkyleneoxy group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229940025084 amphetamine Drugs 0.000 description 1
• 210000004727 amygdala Anatomy 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 229960000793 aniracetam Drugs 0.000 description 1
• ZXNRTKGTQJPIJK-UHFFFAOYSA-N aniracetam Chemical compound C1=CC(OC)=CC=C1C(=O)N1C(=O)CCC1 ZXNRTKGTQJPIJK-UHFFFAOYSA-N 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000003502 anti-nociceptive effect Effects 0.000 description 1
• 230000000561 anti-psychotic effect Effects 0.000 description 1
• 239000001961 anticonvulsive agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000019789 appetite Nutrition 0.000 description 1
• 230000036528 appetite Effects 0.000 description 1
• 230000009118 appropriate response Effects 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 239000012300 argon atmosphere Substances 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 125000005165 aryl thioxy group Chemical group 0.000 description 1
• 125000004104 aryloxy group Chemical group 0.000 description 1
• YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 1
• 238000012093 association test Methods 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 239000003693 atypical antipsychotic agent Substances 0.000 description 1
• 229940127236 atypical antipsychotics Drugs 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 239000000022 bacteriostatic agent Substances 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 229940092714 benzenesulfonic acid Drugs 0.000 description 1
• 150000008316 benzisoxazoles Chemical class 0.000 description 1
• WXNOJTUTEXAZLD-UHFFFAOYSA-L benzonitrile;dichloropalladium Chemical compound Cl[Pd]Cl.N#CC1=CC=CC=C1.N#CC1=CC=CC=C1 WXNOJTUTEXAZLD-UHFFFAOYSA-L 0.000 description 1
• 235000019400 benzoyl peroxide Nutrition 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• YTFJQDNGSQJFNA-UHFFFAOYSA-L benzyl phosphate Chemical compound [O-]P([O-])(=O)OCC1=CC=CC=C1 YTFJQDNGSQJFNA-UHFFFAOYSA-L 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 230000037237 body shape Effects 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 230000009400 cancer invasion Effects 0.000 description 1
• 239000007894 caplet Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 235000010418 carrageenan Nutrition 0.000 description 1
• 229920001525 carrageenan Polymers 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000013043 chemical agent Substances 0.000 description 1
• 239000012069 chiral reagent Substances 0.000 description 1
• 230000000718 cholinopositive effect Effects 0.000 description 1
• QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 230000003930 cognitive ability Effects 0.000 description 1
• 238000009225 cognitive behavioral therapy Methods 0.000 description 1
• 230000037411 cognitive enhancing Effects 0.000 description 1
• 230000036992 cognitive tasks Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 208000030251 communication disease Diseases 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 239000012050 conventional carrier Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 125000000392 cycloalkenyl group Chemical group 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000005595 deprotonation Effects 0.000 description 1
• 238000010537 deprotonation reaction Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 229940119751 dextroamphetamine sulfate Drugs 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• JAEHVOBOWZVTFO-UHFFFAOYSA-N diazonio-[3-ethoxy-1-(4-fluorofuran-2-yl)-3-oxoprop-1-en-2-yl]azanide Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC(F)=CO1 JAEHVOBOWZVTFO-UHFFFAOYSA-N 0.000 description 1
• RUCCAFSTHZZMHX-UHFFFAOYSA-N diazonio-[3-ethoxy-1-[4-(hydroxymethyl)furan-2-yl]-3-oxoprop-1-en-2-yl]azanide Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CC(CO)=CO1 RUCCAFSTHZZMHX-UHFFFAOYSA-N 0.000 description 1
• JQKJEPJLCSCBGW-UHFFFAOYSA-N dibutoxy(ethenyl)borane Chemical compound CCCCOB(C=C)OCCCC JQKJEPJLCSCBGW-UHFFFAOYSA-N 0.000 description 1
• WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• UCQFCFPECQILOL-UHFFFAOYSA-N diethyl hydrogen phosphate Chemical compound CCOP(O)(=O)OCC UCQFCFPECQILOL-UHFFFAOYSA-N 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 208000035548 disruptive behavior disease Diseases 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 235000006694 eating habits Nutrition 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• BJACDGFOTRXWLR-UHFFFAOYSA-N ethyl 1-(1-phenylethyl)-6H-pyrrolo[2,3-c]pyrazole-5-carboxylate Chemical compound C1=2NC(C(=O)OCC)=CC=2C=NN1C(C)C1=CC=CC=C1 BJACDGFOTRXWLR-UHFFFAOYSA-N 0.000 description 1
• KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 1
• CEOZSWLHUWRAHZ-UHFFFAOYSA-N ethyl 2-azido-3-[4-(2-phenylethyl)furan-2-yl]prop-2-enoate Chemical compound O1C(C=C(C(=O)OCC)N=[N+]=[N-])=CC(CCC=2C=CC=CC=2)=C1 CEOZSWLHUWRAHZ-UHFFFAOYSA-N 0.000 description 1
• CPLDTCZGUSCXFY-UHFFFAOYSA-N ethyl 2-azido-3-[4-[2-(4-chlorophenyl)ethyl]thiophen-3-yl]prop-2-enoate Chemical compound CCOC(=O)C(N=[N+]=[N-])=CC1=CSC=C1CCC1=CC=C(Cl)C=C1 CPLDTCZGUSCXFY-UHFFFAOYSA-N 0.000 description 1
• HVJJYOAPXBPQQV-UHFFFAOYSA-N ethyl 2-azidoacetate Chemical compound CCOC(=O)CN=[N+]=[N-] HVJJYOAPXBPQQV-UHFFFAOYSA-N 0.000 description 1
• HDQJHQCDPZOMJA-UHFFFAOYSA-N ethyl 3-(hydroxymethyl)-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(CO)C2=C1C=C(C(=O)OCC)N2 HDQJHQCDPZOMJA-UHFFFAOYSA-N 0.000 description 1
• OQYHOTLOKXSWKL-HYXAFXHYSA-N ethyl 3-[(z)-prop-1-enyl]-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(\C=C/C)C2=C1C=C(C(=O)OCC)N2 OQYHOTLOKXSWKL-HYXAFXHYSA-N 0.000 description 1
• BZCFLVAMRFKPBH-UHFFFAOYSA-N ethyl 3-ethyl-2-fluoro-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C(F)=C(CC)C2=C1C=C(C(=O)OCC)N2 BZCFLVAMRFKPBH-UHFFFAOYSA-N 0.000 description 1
• XQWPLXGMFLEVMU-UHFFFAOYSA-N ethyl 3-fluoro-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(F)C2=C1C=C(C(=O)OCC)N2 XQWPLXGMFLEVMU-UHFFFAOYSA-N 0.000 description 1
• NRGDCPHIUQSYOH-UHFFFAOYSA-N ethyl 3-formyl-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C=C(C=O)C2=C1C=C(C(=O)OCC)N2 NRGDCPHIUQSYOH-UHFFFAOYSA-N 0.000 description 1
• MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 230000002964 excitative effect Effects 0.000 description 1
• 230000002461 excitatory amino acid Effects 0.000 description 1
• 239000003257 excitatory amino acid Substances 0.000 description 1
• 230000010326 executive functioning Effects 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 230000008921 facial expression Effects 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 230000014061 fear response Effects 0.000 description 1
• 239000012065 filter cake Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 210000001061 forehead Anatomy 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 150000002240 furans Chemical class 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 208000037870 generalized anxiety Diseases 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 230000006589 gland dysfunction Effects 0.000 description 1
• 229940097043 glucuronic acid Drugs 0.000 description 1
• 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000003979 granulating agent Substances 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
• 239000008241 heterogeneous mixture Substances 0.000 description 1
• 230000000971 hippocampal effect Effects 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 229940071870 hydroiodic acid Drugs 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 230000035879 hyperinsulinaemia Effects 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
• 208000034783 hypoesthesia Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 239000005457 ice water Substances 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 239000007924 injection Substances 0.000 description 1
• 238000002347 injection Methods 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 208000001286 intracranial vasospasm Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 230000026045 iodination Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
• 230000003447 ipsilateral effect Effects 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
• ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
• VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
• 229950006874 kainic acid Drugs 0.000 description 1
• 229960003299 ketamine Drugs 0.000 description 1
• 150000004715 keto acids Chemical class 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 230000001535 kindling effect Effects 0.000 description 1
• 239000004310 lactic acid Substances 0.000 description 1
• 235000014655 lactic acid Nutrition 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 210000000088 lip Anatomy 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 230000006742 locomotor activity Effects 0.000 description 1
• 230000007787 long-term memory Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 210000005171 mammalian brain Anatomy 0.000 description 1
• 229960002510 mandelic acid Drugs 0.000 description 1
• 230000005056 memory consolidation Effects 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
• GABXQZVOQAYXAG-UHFFFAOYSA-N methyl 2-[(dimethylamino)methyl]-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound O1C(CN(C)C)=CC2=C1C=C(C(=O)OC)N2 GABXQZVOQAYXAG-UHFFFAOYSA-N 0.000 description 1
• SBBZXGMGOKVVOB-UHFFFAOYSA-N methyl 4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound S1C=CC2=C1C=C(C(=O)OC)N2 SBBZXGMGOKVVOB-UHFFFAOYSA-N 0.000 description 1
• RJZIYUWKRUYUFL-UHFFFAOYSA-N methyl 6-[(dimethylamino)methyl]-4h-thieno[3,2-b]pyrrole-5-carboxylate Chemical compound C1=CSC2=C1NC(C(=O)OC)=C2CN(C)C RJZIYUWKRUYUFL-UHFFFAOYSA-N 0.000 description 1
• LNWIUIFDUWVWGQ-UHFFFAOYSA-N methyl 6-iodo-4h-furo[3,2-b]pyrrole-5-carboxylate Chemical compound C1=COC2=C1NC(C(=O)OC)=C2I LNWIUIFDUWVWGQ-UHFFFAOYSA-N 0.000 description 1
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
• 229960001344 methylphenidate Drugs 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000007932 molded tablet Substances 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 125000006682 monohaloalkyl group Chemical group 0.000 description 1
• 229960005181 morphine Drugs 0.000 description 1
• 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
• 239000000472 muscarinic agonist Substances 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• 208000013465 muscle pain Diseases 0.000 description 1
• 230000036640 muscle relaxation Effects 0.000 description 1
• 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 125000006574 non-aromatic ring group Chemical group 0.000 description 1
• 239000002664 nootropic agent Substances 0.000 description 1
• 230000001777 nootropic effect Effects 0.000 description 1
• 210000001331 nose Anatomy 0.000 description 1
• 230000001473 noxious effect Effects 0.000 description 1
• 238000012587 nuclear overhauser effect experiment Methods 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 239000004533 oil dispersion Substances 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 125000000962 organic group Chemical group 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 229960001227 oxiracetam Drugs 0.000 description 1
• IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 239000004031 partial agonist Substances 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 235000014594 pastries Nutrition 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000008289 pathophysiological mechanism Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 230000008447 perception Effects 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 210000002856 peripheral neuron Anatomy 0.000 description 1
• 210000003200 peritoneal cavity Anatomy 0.000 description 1
• 238000011170 pharmaceutical development Methods 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 238000001050 pharmacotherapy Methods 0.000 description 1
• 229950010883 phencyclidine Drugs 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 229960001697 physostigmine Drugs 0.000 description 1
• PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
• 229960001416 pilocarpine Drugs 0.000 description 1
• 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
• 229960004526 piracetam Drugs 0.000 description 1
• 239000002798 polar solvent Substances 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 125000006684 polyhaloalkyl group Polymers 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 230000036278 prepulse Effects 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000007425 progressive decline Effects 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
• 230000001107 psychogenic effect Effects 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
• ZSKGQVFRTSEPJT-UHFFFAOYSA-N pyrrole-2-carboxaldehyde Chemical compound O=CC1=CC=CN1 ZSKGQVFRTSEPJT-UHFFFAOYSA-N 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 238000009256 replacement therapy Methods 0.000 description 1
• 206010048628 rheumatoid vasculitis Diseases 0.000 description 1
• 244000195895 saibo Species 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 229930195734 saturated hydrocarbon Natural products 0.000 description 1
• 210000004761 scalp Anatomy 0.000 description 1
• 210000003497 sciatic nerve Anatomy 0.000 description 1
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
• 229960002646 scopolamine Drugs 0.000 description 1
• 208000012672 seasonal affective disease Diseases 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 229960001153 serine Drugs 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 231100000872 sexual dysfunction Toxicity 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000006403 short-term memory Effects 0.000 description 1
• 239000010703 silicon Substances 0.000 description 1
• 230000005586 smoking cessation Effects 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• 239000011343 solid material Substances 0.000 description 1
• 210000000273 spinal nerve root Anatomy 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 208000005809 status epilepticus Diseases 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 208000011117 substance-related disease Diseases 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 210000000106 sweat gland Anatomy 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 230000003956 synaptic plasticity Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 229960001685 tacrine Drugs 0.000 description 1
• 229960003565 tacrine hydrochloride Drugs 0.000 description 1
• YLJREFDVOIBQDA-UHFFFAOYSA-O tacrine(1+) Chemical compound C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-O 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• MFPWEWYKQYMWRO-UHFFFAOYSA-N tert-butyl carboxy carbonate Chemical compound CC(C)(C)OC(=O)OC(O)=O MFPWEWYKQYMWRO-UHFFFAOYSA-N 0.000 description 1
• HZCHIDSJVMPUQO-UHFFFAOYSA-N tert-butyl-[(5-fluorothiophen-2-yl)methoxymethyl]-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)COCC1=CC=C(F)S1 HZCHIDSJVMPUQO-UHFFFAOYSA-N 0.000 description 1
• MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
• ZYDKYFIXEYSNPO-UHFFFAOYSA-N tert-butyl-dimethyl-prop-2-ynoxysilane Chemical compound CC(C)(C)[Si](C)(C)OCC#C ZYDKYFIXEYSNPO-UHFFFAOYSA-N 0.000 description 1
• BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• OSBSFAARYOCBHB-UHFFFAOYSA-N tetrapropylammonium Chemical compound CCC[N+](CCC)(CCC)CCC OSBSFAARYOCBHB-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• WEMNATFLVGEPEW-UHFFFAOYSA-N thiophene Chemical class C=1C=CSC=1.C=1C=CSC=1 WEMNATFLVGEPEW-UHFFFAOYSA-N 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 208000004371 toothache Diseases 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000007070 tosylation reaction Methods 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical group C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 238000005292 vacuum distillation Methods 0.000 description 1
• 230000001457 vasomotor Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 230000031836 visual learning Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• ZFNVDHOSLNRHNN-UHFFFAOYSA-N xi-3-(4-Isopropylphenyl)-2-methylpropanal Chemical compound O=CC(C)CC1=CC=C(C(C)C)C=C1 ZFNVDHOSLNRHNN-UHFFFAOYSA-N 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1